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V. Summary 
      It is increasingly accepted that the alveolar epithelial cell plays a major role in the 
pathogenesis of idiopathic pulmonary fibrosis (IPF), a dismal disease with                     
an average survival time of ~ 3 years and a progressive decline in lung function and 
exercise capacity. In IPF, chronic injury of alveolar type II cells (AECII) seems to cause 
disturbed alveolar re-epithelialization (1). It appears that profoundly increased epithelial 
apoptosis, which occurs due to epithelial injury, causes accelerated epithelial cell 
proliferation and further apoptosis (2, 3 and 4). 
       The Notch signaling functions as a mediator of a cell-cell communication. The 
Notch pathway is known to be involved in proliferation, cell death, stem cell 
maintenance and differentiation during embryonic and adult development (5-8). In 
addition the Notch network has already been identified to play a role in some chronic 
lung diseases such as COPD or PAH (9, 10). Until now, the Notch signaling pathway 
has not been investigated in IPF. In particular, the impact of Notch activation on 
alveolar epithelial proliferation and apoptosis has yet not been analyzed. 
      The present study was undertaken to evaluate the regulation and the potential role 
of Notch activation in repair processes in IPF lungs. We investigated the cellular 
regulation of the Notch signaling pathway on mRNA, protein and immunohistochemical 
level (IPF vs. donor lungs; bleomycin-treated vs. control mice lungs). Proliferation and 
survival of an AECII and AECII-like cell line (MLE 12) was investigated after in vitro 
transfection with Notch1 ICD, POFUT1 siRNA and DAPT (γ-secretase inhibitor) 
treatment. 
      Our transcriptome data proved differential regulation of the Notch signaling 
pathway in microdisected septae from still „normal” appearing areas (representative of 
the early-stage of the disease) of IPF lungs compared to septae of healthy organ donors. 
On protein level, no significant changes in the expression of Notch pathway elements 
were observed with the exception of the intracellular domain of Notch1 receptor 
(NICD1), the ligand DLL1 and the downstream target Hes1, which were found to be 
significantly increased in IPF vs. donor lungs. We also observed increased protein levels 
of NICD1 and Dll1 in lungs of bleomycin-treated mice. Expression of these proteins 
was mainly restricted to AECII of fibrotic lungs. Moreover on the IHC level, expression 
of NICD1 and DLL1 proteins seems to be increased in AECII in IPF as compared to 
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controls. Furthermore, we observed a characteristic staining pattern, where 
subpopulation of AECII cells expressed Notch1 in cytoplasm and neighboring AECII 
cell showed localization of this receptor in the nucleus. Most importantly, observations 
made after NICD1 overexpression or Notch pathway inhibition in the MLE 12 alveolar 
epithelial cell line and mouse primary AECII cells isolated from bleomycin-challenged 
mice indicate that Notch plays a major role in uncontrolled AECII proliferation in vitro. 
In addition, there was no influence of the Notch signaling pathway on epithelial 
apoptosis. Furthermore, genome wide mRNA microarray analysis of NICD1-
overexpressing MLE 12 cells revealed differential regulation of the MAPK pathway. 
We found that NICD1 overexpression in MLE 12 cells induced phosphorylation of Erk5. 
Therefore, we can speculate that Erk5 may be a downstream effector of Notch1 
activation, involved in increased alveolar epithelial cell proliferation. 
      Our findings demonstrate for the first time a potential role of the Notch signaling 
pathway in the re-epithelialization process in the lung, which may indicate involvement 
of Notch on pathogenesis of pulmonary fibrosis.  
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VI. Zusammenfassung 
         Es findet zunehmend Akzeptanz, dass die alveolaren Epithelzellen eine 
wesentliche Rolle in der Pathogenese der idiopathischen pulmonalen Fibrose (IPF) 
spielen, einer prognostisch ungünstig verlaufenden Krankheit mit einer medianen 
Überlebenszeit von etwa 3 Jahren und einer fortschreitenden Abnahme der 
Lungenfunktion und Belastbarkeit. Bei der IPF scheint eine chronische Schädigung der 
alveolaren TypII Zellen (AECII) eine gestörte alveolare Reepithelisierung zu 
verursachen (1). Anscheinend bewirkt stark vermehrte Apoptose, hervorgerufen durch 
Schädigung des Epitheliums, beschleunigte Epithelzellvermehrung und weitere 
Apoptose (2, 3 und 4).  
          Die Notch-Signalkaskade fungiert als Vermittler der Zell-Zell-Kommunikation. 
Bekanntermaßen ist der Notch-Signalweg in Proliferation, Zelltod, Stammzellerhaltung 
und -differenzierung  während der embryonalen und adulten Entwicklung involviert             
(5-8). Des Weiteren spielt er eine Rolle bei einigen chronischen Lungenerkrankungen, 
wie COPD oder PAH (9, 10). Bisher wurde die Rolle des Notch-Signalwegs im 
Zusammenhang mit der IPF, insbesondere der Einfluss der Notch-Aktivierung auf die 
Proliferation und Apoptose der alveolaren Epithelzellen, noch nicht analysiert. 
          In der vorliegenden Arbeit sollte die Regulation und die mögliche Rolle der 
Notch-Aktivierung bei Regenerationsprozessen in IPF Lungen untersucht werden. Die 
zelluläre Regulation des Notch-Signalwegs wurde auf mRNA- und Proteinebene sowie 
auf immunhistochemischer Ebene untersucht (IPF vs. Donorlungen; Lungen von 
Bleomycin-behandelten Mäusen und Kontrollen). Proliferation und Überleben von 
AECII und einer AECII ähnlichen Zelllinie (MLE 12) wurden nach in vitro 
Transfektion mit Notch1 ICD, POFUT1 siRNA und nach Behandlung mit einem           
γ-Sekretase-Inhibitor (DAPT) untersucht. 
          Anhand unserer Transkriptomdaten konnten wir unterschiedliche Regulation des 
Notch-Signalwegs in Septen (durch Mikrodissektion erhalten) normal erscheinender 
Bereiche von IPF Lungen (einem frühen Krankheitsstadium der IPF entsprechend) im 
Vergleich zu Septen gesunder Spenderlungen nachweisen. Auf Proteinebene konnten 
wir keine signifikanten Unterschiede in der Expression von Bestandteilen der Notch-
Signalkaskade feststellen, mit Ausnahme der intrazellulären Domäne des Notch1 
Rezeptors (NICD1), des DLL1 Liganden und des downstream target Hes1, welche im 
Zusammenfassung 
 
 XIII 
Vergleich zu Donorlungen in IPF Lungen signifikant erhöht waren. Ebenso zeigten sich 
auf Proteinebene erhöhte Werte von NICD1 und Dll1 in Lungen von Bleomycin-
behandelten Mäusen. Die Expression dieser Proteine war hauptsächlich auf AECII 
fibrotischer Lungen beschränkt. Im Vergleich zu Spenderlungen scheint die Expression 
von NICD1 und DLL1 auf immunhistochemischer Ebene in IPF-Lungen erhöht zu sein. 
Des Weiteren beobachteten wir ein charakteristisches Färbemuster, bei dem ein Teil der 
AECII Notch1 im Zytoplasma exprimierte, während bei benachbarten AECII dieser 
Rezeptor im Nukleus lokalisiert war. 
          Wesentlich sind Beobachtungen nach Überexpression von NICD1 oder 
Inhibition der Notch-Signalkaskade in der MLE 12 Zelllinie und in von Bleomycin-
behandelten Mäusen isolierten AECII, die zeigen, dass Notch in vitro eine wichtige 
Rolle in der unkontrollierten Proliferation von AECII Zellen spielt. Der Notch 
Signalweg hatte keinen Einfluss auf die Apoptose der Epithelzellen. Weiterhin zeigte 
eine genomweite mRNA-Analyse mit Mikroarrays von NICD1 überexprimierenden 
MLE 12 Zellen differenzielle Regulation des MAPK Signalwegs. NICD1-
Überexpression in MLE 12 Zellen induzierte eine Erk5-Phosphorylierung. Daher 
können wir vermuten, dass Erk5 ein in die erhöhte Proliferation der alveolaren 
Epithelzellen involvierter Downstream-Effektor der Notch1 Aktivierung ist. 
          Unsere Ergebnisse zeigen erstmals eine mögliche Rolle des Notch-Signalwegs in 
Reepithelisierungsprozessen der Lunge. Dies könnte auf eine Beteiligung von Notch an 
der Pathogenese der pulmonalen Fibrose hindeuten. 
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1. Introduction 
1.1. Idiopathic pulmonary fibrosis 
1.1.1. Characteristics of idiopathic pulmonary fibrosis 
           Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung 
disease (11). It belongs to a family of lung disorders known as interstitial lung diseases 
(ILD) or, more precisely, diffuse parenchymal lung diseases (DPLD). IPF belongs to the 
group of idiopathic interstitial pneumonia (IIP) and is related to the pathologic pattern 
known as usual interstitial pneumonia (UIP). Until now, the etiology of IIP has not been 
discovered (12). IPF affects slightly more men than women and increases with age. 
Most commonly the disease develops after the fifth decade of life, affecting patients 
over 60 years of age (13). So far it has been demonstrated that IPF does not occur in any 
particular ethnic group or social environment. It is known that IPF affects around                 
5 million people worldwide and over the last decade, the number of IPF diagnosed 
patients has been on the rise (14).  
           IPF patients experience breathlessness which is commonly initially attributed to 
aging, cardiac disease, or emphysema, resulting in a typical delay in diagnosis. Patients 
can also experience a dry cough (15). In around 90% of patients with IPF 
gastroesophageal acid reflux can be present (16). Another visible symptom of IPF can 
also be finger clubbing found in almost every IPF patient. In the end-stage the disease 
pulmonary hypertension may develop with classic signs of right heart failure (15). 
Initial development of symptoms is usually slow, but may become more rapid with time. 
The prognosis of IPF patients is ~ 3-5 years after diagnosis (11). 
            The diagnostic standard of IPF consists of clinical, radiological and 
pathological assessments. According to procedure, the diagnosis of IPF can be 
considered definitive only if other known causes of interstitial lung disease                
(e.g. connective tissue disease, environmental exposure) have been ruled out,                 
a high-resolution computed tomography (HRCT) has forwarded a definite UIP pattern 
consistent with the diagnosis and/or a surgical lung biopsy forwarded                                    
a histological pattern consistent with UIP (especially if HRCT is not prototypic) (1). 
           Although the cause of IPF remains unknown, major progress has been made in 
cellular and molecular biology on this subject. Nevertheless, although the course of the 
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disease is variable, the ultimate fate is respiratory failure and death (11). With the 
exception of pirfenidone no effective treatment exists for IPF and the only option for 
affected patients is lung transplantation (1, 17).  
1.1.2. Histopathological changes in idiopathic pulmonary fibrosis 
            The histopathological lesion associated with IPF is known as usual interstitial 
pneumonia (UIP) (1). It was observed that a UIP pattern is not exclusive to IPF. It is 
also found in other diseases such as scleroderma and occupational lung diseases such as 
asbestosis (18). The UIP pattern is characterized by spatial heterogenity with still 
normal appearing lung areas directly adjacent to areas of fibrosis (Figure 1.1.A). 
Alveolar septal thickening, modest interstitial inflammation, and honeycomb changes 
(Figure 1.1. and Figure 1.2.) are also typical signs of a UIP pattern (13). Additionally, 
emphysema or respiratory bronchiolitis can been seen when the patient is a former or 
active smoker (1). The inflammatory process is typically mild and consists primarily of 
lymphocytes and plasma cells, but neutrophils and eosinophils may also be present (19). 
 
Figure 1.1. Histopathological changes observed in IPF. 
A. Low-magnification photomicrograph of UIP showing the characteristic heterogeneous involvement of 
the parenchyma. Zones of interstitial fibrosis are seen alternating with areas of normal lung. B. Higher-
magnification demonstrates hyperplastic alveolar epithelium. C. Higher-magnification shows fibroblast 
foci (modified from 21 and 22). 
 
             At the border between fibrotic and normal lung are regions with accumulation 
of fibroblasts/myofibroblasts, termed fibroblastic foci (Figure 1.1.C. and Figure 1.2.) 
(19). It was observed that IPF patients with higher numbers of fibroblastic foci in lung 
biopsies had a poorer prognosis (20). An injured alveolar epithelium with hyperplastic 
type II pneumocytes is also one of the characteristic elements seen in areas of active 
fibrosis (Figure 1.1.B) (21). Further UIP features are microscopic honeycomb changes 
A B C 
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(Figure 1.2.). They are characterized by enlarged, cystic airspaces covered by hyper 
plastic type II pneumocytes as a bronchiolized epithelium (1).  
 
                                 
 
Figure 1.2. UIP pattern demonstrates the characteristic variegated appearance. 
Low-magnification photomicrograph showing the honeycomb change (arrowheads) present in the area of 
dense fibrosis next to the pleural surface. A fibroblast focus (arrow) is seen at the leading edge of 
advancing fibrosis (19). 
1.1.3. Pathogenesis of idiopathic pulmonary fibrosis 
           The pathogenetic mechanisms of idiopathic pulmonary fibrosis are incompletely 
understood. The present paradigm proposes that one of the reasons for development of 
IPF may be sequential alveolar injury (e.g. ER stress (2), DNA damage (3)) which 
afterwards leads to the epithelial cells damage. Under normal conditions, the repair 
process is followed by a wound-healing response, where the integrity of the epithelial 
barrier is initiated to restore, followed by a burst of pro-inflammatory and fibro-
proliferative mediators. In IPF, the wound-healing process seems to be disturbed (1). 
The normal wound-healing process involves re-epithelialization of the compromised 
area through epithelial and fibroblast cell proliferation, migration and differentiation. 
Fibroblast cells differentiate into myofibroblasts and extracellular matrix (ECM) 
deposition occurs. Furthermore, in normal wound healing, myofibroblasts undergo 
apoptosis and ECM is at least partially removed. It allows epithelial cells to migrate and 
re-epithelializate to complete tissue repair. In IPF, the above mentioned process does 
not occur and myofibroblast foci are formed in the injured areas, ECM continues to 
accumulate, the apoptotic process is impaired and proper re-epithelialization can not 
take place (Figure 1.3.) (23, 24). There are a few factors that may modify wound 
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healing and the level of parenchymal fibrosis (Figure 1.4.). One of them can be the type 
of inflammatory response. IPF is thought to closely resemble a Th2-type immune 
response (eosinophils, mast cells and Th2 cytokines interleukin-4 and interleukin-13) 
(19, 25). Up to 15% of IPF cases have a familial background and are due to mutations 
which – in part – have already been disclosed (e.g. SFTPA, SFTPC, TERC) (26). These 
are the main pathogenic mechanisms that underlay IPF (Figure 1.4.). As                         
a result of these abnormalities, gas exchange is impaired and a progressive worsening of 
pulmonary function and prognosis occur (1). 
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Figure 1.3. Hypothetical scheme of the main pathogenic events in IPF/UIP.  
Briefly, uncharacterized unknown insults provoke multiple epithelial injuries. In this microenvironment, 
epithelial cells are abnormally activated and produce diverse growth factors and chemokines inducing 
fibroblast migration and proliferation and changes in cell phenotype. Finally, fibroblasts/myofibroblasts 
secrete excessive amounts of extracellular matrix components and afterwards matrix degradation does not 
occur. As a result aberrant remodelling of the lung parenchyma occurs (24). 
 
 
 
                                    
 
 
Figure 1.4. Hypothesis for the pathogenesis of IPF (modified from 23). 
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1.1.4. Alveolar epithelial cells as one of the key effector cells in 
idiopathic pulmonary fibrosis 
             In adult lungs, type 1 and type 2 alveolar cells constitute the distal lung 
epithelium. Type I cells cover around 90% of the alveolar surface of the peripheral lung. 
Those cells interface with pulmonary capillaries, provide an intact surface permeable to 
gases. Type 1 cells are also highly susceptible to injury. Type 2 cells (AECII), appear as 
large squamous cells, which can be found in the corners of alveoli and are found near to 
mesenchymal cells. They synthesize and secrete pulmonary surfactant, are more 
resistant to injury and serve as progenitor cells for type 1 alveolar cell (24, 27 and 28). 
Type 2 cells take part in the sodium transport from apical to basolateral cell surfaces to 
minimize alveolar fluid and participate in the effector phase of the immune response, 
producing molecules involved in the innate host defense (29, 30).  
             IPF lungs demonstrate major changes in the alveolar epithelium. Hyperplastic 
type 2 pneumocytes with abundant cytoplasm, large hyperchromatic nuclei and 
prominent nucleoli form the majority of the epithelium (Figure 1.1.B). One may also 
observe large and elongated epithelial cells (fibroblast-like) and flattened and attenuated 
epithelial cells overlying the fibroblastic foci (1, 21, 22 and 29). 
             Following injury, appropriate repair of the alveolar epithelium is required to 
prevent excess of mesenchymal activation (Figure 1.4.). Prior to provisional matrix 
remodeling and removing, epithelial cells migrate above basal layers to restore the 
damaged area of the lung (11). As was shown previously, alveolar                                   
re-epithelialization appears severely disturbed in IPF. The reasons of the abnormal 
reactions of the alveolar epithelial cells (AECs) are unknown, but some of them may be 
the answer to the initial insult, whereas others may be the result of accelerated epithelial 
cell proliferation/migration which occurs after epithelial injury. Major proof of this 
hypothesis is a high rate of proliferating cell nuclear antigen (PCNA) observed in the 
hyperplastic epithelium of the honeycomb lesions. This can be a sign of accelerated 
epithelial cell proliferation which occurs in these lesions (4). In addition, recent data 
shows that the apoptosis process may also take part in the absence of proper re-
epithelialization. Labeling of fragmented DNA and activated caspase 3 in AECII cells 
which are located in areas of dense fibrosis was found in lung biopsies obtained from 
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IPF patients (2, 3). The apoptotic alveolar epithelial cells are detected mostly in areas 
next to fibroblasts foci (31). 
1.1.5. Bleomycin model of pulmonary fibrosis 
           Animal models play a significant role in the investigation of chronic pulmonary 
diseases. Different models of pulmonary fibrosis in mice are available but none of them 
mimic all features of human IPF. Among these mouse models are radiation, silica or 
asbestos induced, gene transfer of fibrogenic cytokines, various transgenic mice lines 
and, still considered as the gold standard, the bleomycin model of lung fibrosis (32).  
             Bleomycin is a chemotherapeutic antibiotic, produced by Streptomyces 
verticillus bacterium (33). It is used in animal models of IPF partially because lung 
fibrosis is one of the major adverse drug effects of bleomycin in human cancer therapy. 
Bleomycin causes single- and double-strand DNA breaks, interrupts the cell cycle and 
leads to epithelial apoptosis (34). Bleomycin causes a primary inflammatory response 
(pro-inflammatory cytokines: interleukin-1, tumor necrosis factor-α, interleukin-6, 
interferon-γ) and fibrotic reactions (transforming growth factor-β1, fibronectin, 
procollagen-1) within a short period of time (peak around day 14; Figure 1.5.) (36, 37). 
The switch between inflammation and the fibrosis phase is around day 9 after 
bleomycin treatment (35).  
              However, a major disadvantage of this model is that fibrosis does not develop 
in all animals and the disease may be self-limiting. The advantages of the bleomycin 
model are that it is well characterized, has clinical relevance; many delivery routes are 
possible for the induction of fibrosis and the time frame for expansion of fibrosis is only 
14 – 28 days (36). 
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Figure 1.5. Characteristic pathology seen in bleomycin model. 
Trichrome staining of a lung section from a control C57Bl/6 mouse and mouse sacrificed 14 days after 
belomycin treatment. The blue staining represents collagen deposition (modified from 37). 
1.2. The Notch signaling pathway 
 The Notch signaling pathway functions as a mediator of cell-cell communication. 
Notch signaling promotes or represses proliferation, cell death, stem cell maintenance 
and differentiation during embryonic and adult development (5, 6, 7 and 8). Because of 
the importance of Notch in numerous processes in a wide range of tissues, gain or loss 
of Notch signaling elements have been related to several human disorders as 
developmental syndromes (e.g. Alagille, Familial Aortic Valve Disease) (38, 39), adult 
onset diseases (e.g. CADASIL) (40) and cancers (41, 42). 
  A characteristic feature of Notch signaling is that functionality does not 
dependent on secondary messengers. Levels of activity are in the most part dependent 
on the nuclear concentration of NICD which, in turn, is dependent on enzymatic 
cleavage of the receptor upon binding of the ligand. Although NICD levels are 
extremely low, it has an extremely strong impact on most tissues. The preferable 
method to monitor NICD levels is immunodetection with antibodies raised against the 
epitope generated by the S3/S4 cleavage (43). Additionally, Notch signaling activity is 
modulated by glycosylation, differential intracellular trafficking, and ubiquitin-
dependent degradation (44, 45). 
 
 
 
 
Control Bleomycin day 14 
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1.2.1. Notch receptors 
The Notch receptor acts as a transmembrane receptor as well as                           
a transcription factor. The Notch cascade is composed of notch receptors, notch ligands 
and intracellular proteins converting the notch signal to the cell's nucleus. In 
mammalian cells, there are four different notch receptors (Notch1, Notch2, Notch3, and 
Notch4) (44). 
Notch receptors are modified in the endoplasmic reticulum (ER) and the Golgi 
apparatus during the secretion to the membrane. Notch is translated inside                            
ER and then glycosylated by an O-fucosyltransferase (O-Fut1) and                                        
an O–glucosyltransferase. Next, the receptor is translocated into the Golgi apparatus, 
where it is cleaved by a Furin protease at the S1 site and further modified by the               
N–acetylglucosaminyltransferase. At the cell surface, Notch is present as                        
a heterodimer, consisting of the extracellular region of up to 36 epidermal growth factor 
(EGF)-like repeats (involved in ligand interaction) and three juxtamembrane repeats 
known as Lin-12-Notch (LNR). Those repeats linked non-covalently by                                   
a heterodimerization region to the rest of the molecule (44, 46). Intracellular part of 
Notch receptors contain the region called RAM (RBPjk Associate Molecule), 
additionally seven ankyrin repeats flanked by nuclear localization signals, a PEST 
domain and a transactivation domain (TAD) (Figure 1.6.A.) (47, 48). 
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Figure 1.6. Structure of Notch and its ligands.  
A. Notch receptors. Notch is composed by up to 36 EGF-like repeats. In close proximity to                         
a cysteine-rich region are heterodimerization domains. A region called RAM (RBPjk Associate Molecule) 
followed by repeated structural motifs named Ankyrin repeats (mediate the interaction between Notch 
and RPBJκ), a transactivation domain (TAD) and a PEST domain. The PEST domain is involved in the 
degradation of Notch. B. Notch ligands. The N-terminal region of the ligands contains a conserved ~100 
residue MNNL (module at the N-terminus of Notch ligands) domain. A cysteine-rich module called a 
DSL domain near the N-terminus, followed by a series of iterated EGF-like repeats. Serrate and Jagged 
ligands also contain a cysteine-rich between the EGF-like repeats and the transmembrane domain, 
whereas the Delta class of ligands does not (modified from 47). 
1.2.2. Notch ligands 
There are 5 canonical Notch ligands: Jagged1, Jagged2, DLL1, DLL3 and DLL4 
(Figure 1.6.B). Like receptor molecules, the ligands are also transmembrane proteins 
(49). The ligand region of most significance for Notch signaling interactions is an 
extracellular cysteine rich region called DSL present in Delta and Jagged homologues. 
DSL mediates the interaction with Notch EGF-like repeats (47, 50 and 51). 
The structural difference among the Delta and Jagged ligands is that                   
the Jagged1 and Jagged2 contain a greater number of EGF repeats in the extracellular 
region and also insertions within them. Near to the membrane region, the Jagged 
molecules contain a cysteine-rich region that is lacking in the Delta ligands                 
(Figure 1.6.B) (49). It has also been suggested that other proteins can act as Notch 
ligands. Convincing evidence shows that F3/contactin may be one of such examples 
(52). 
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1.2.3. Notch target genes 
Only a few downstream genes of the Notch signaling pathway have been 
identified, despite the large number of developmental processes that are regulated by 
Notch. In the canonical pathway, RBP-Jκ connects with NICD and together they act as 
a transcriptional activator. The RBP-Jκ-NICD complex turns on expression of Notch 
signaling target genes, such as the Hes (Hes1, Hes5 and Hes7) and Hey family genes 
(Figure 1.7.). These genes encode helix-loop-helix transcription factors that function as 
transcriptional repressors, directly affecting cell fate decisions as Notch effectors (45, 
53, 54),  
There are also other Notch target genes, such as NRARP and Deltex-1 (negative 
regulators of Notch signaling) (55, 56). Notch target genes, which are implicated in 
cancer include c-myc (57, 58), cyclinD1 (59) and p21/Waf1 (60). Other downstream 
genes are NFkB2 (61), Ifi- 202, Ifi-204, Ifi-D3, and ADAM19 (62). A number of other 
genes have been described including Notch1 and Notch3, bcl-2 and E2A (63, 64 and 
65). 
In addition to the canonical Notch pathway (via RBP-Jκ), a non-canonical 
pathway has been observed. One good example is the interactions between Notch and 
Wnt signaling pathways, where transduction of Notch signals is facilitated via Wnt 
pathway components (66, 67).  
 
 
Figure 1.7. The switch model for Notch target gene regulation by RBP-Jκ . 
In the absence of Notch, DNA-bound RBP-Jκ (green) prevents activators from starting transcription.             
Co-repressors, recruited by RBP-Jκ, act by local conversion of chromatin. NICD (orange) is able to 
lighten the repression. RBP-Jκ–NICD complex cooperate with trans-activators to promote transcription 
(68). 
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1.2.4. Mechanisms of Notch signaling 
Signaling occurs when the DSL domain of a ligand (Delta, Jagged) binds and 
interacts with the Notch receptor (69), thus inducing the S2, S3, and S4 cleavages 
(Figure 1.8.). Two kinds of interaction can be distinguished: positive interaction with 
ligand presented by neighboring cells, (trans interactions) mediated by EGF repeats 11–
12 of receptors and inhibitory interaction with a ligand co-expressed in the same cell 
(cis interactions) which is mediated by repeats 24–29 (70). Many of the EGF repeats 
bind calcium ions. They play an important role in determining the structure and affinity 
of Notch receptors to its ligands (71, 72). Interaction between receptor and ligand 
results in shedding of the ectodomain and exposure of an extracellular metalloprotease 
site (S2 site). Notch is then cleaved by transmembrane metalloproteases ADAM. The 
S3/4 cleavage is an intramembranous cleavage mediated by the presenilin-dependent               
γ-secretase complex (73, 74 and 75). This cleavage results in the translocation of the 
intracellular domain of Notch (NICD) into the nucleus. The γ-secretase complex is 
composed of 4 membrane proteins in a 1:1:1:1 stoichiometry of the catalytic component 
presenilin and the three limiting cofactors nicastrin, Pen2 and Aph1 (76, 77). The                   
γ-secretase complex has been detected on the cell membrane and in endocytic 
compartments (44, 78, 79). There is evidence that the S3/4 cleavage can happen on the 
membrane as well as in endocytic components (44).  
After translocation of NICD into the nucleus, the receptor interacts with                        
the transcription factor CSL (CBF1/RBPJk in mammals) by acting as a co-activator of 
the transcription factor (Figure 1.7.) (80). This active complex recruits transcription 
factors including CBP/p300 and PCAF, promoting histone acetylation and increased 
expression of Notch target genes (81, 82 and 83). 
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Figure 1.8. Canonical Notch signaling pathway. 
The Notch receptor binding ligand undergoes several cleavages. The S2 site is mediated by the proteases 
ADAM10 or by TACE (TNF-a-converting enzyme). This catalyzes the processing of Notch in the 
intramembranous S2 and S3 sites by the γ-secretase complex. Thus, the Notch intracellular domain 
(NICD) is translocated into the nucleus where it forces dissociation of repressor proteins from CSL/Rbpjκ. 
NICD and CSL/Rbpjκ form a ternary complex together with Mastermind (Mam) that recruits 
transcription factors activating target gene expression. (45). 
 
1.3. The Notch signaling pathway in lung diseases 
1.3.1. Chronic obstructive pulmonary disease 
As chronic obstructive pulmonary disease (COPD) develops, there are consistent 
changes in the airway epithelial with increased basal and secretory cells, a decrease in 
ciliated cells, a partial shedding of the epithelium and with squamous cell metaplasia 
(84, 85 and 86). In the airway epithelium of smokers and individuals with COPD, high 
amounts of PCNA and an increased rate of both cell division and apoptosis were 
observed (85, 86). Immunohistochemistry analysis of COPD lung tissues revealed 
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protein expression of receptor Notch2, ligand Jag1 and target genes Hes1, Hes5 in the 
airway epithelium. It was shown that key Notch pathway genes were downregulated in 
healthy smokers and smokers with COPD, as compared to nonsmokers (9). 
1.3.2. Asthma 
Asthma is an inflammatory disorder of the conducting airways. A significant 
percentage of asthma is associated with allergic sensitization. The disease is 
characterized by a polarized Th-2 (T-helper-2)-type T-cell response (87). Activation of 
the Notch pathways has been shown to play a role in Th cell differentiation. It was 
demonstrated that Dll4 plays a role in the initial Th2 differentiation as well as in Th2 
cytokine production in an established allergic response (88). 
1.3.3. Pulmonary arterial hypertension 
Pulmonary arterial hypertension (PAH) is described by structural remodeling of 
small pulmonary arteries and arterioles. As a result, the vessel wall is thickened and the 
lumen is occluded because of media thickening (proliferation of vascular smooth 
muscle cells) and intima (endothelial cell) proliferation (89). It was proven that high 
levels of Notch3 are associated with the development of PAH in humans and 
experimental models of this disease. Pulmonary hypertensive vascular pathology in a 
hypoxia mouse model of this disease can be prevented by treatment with a drug which 
blocks Notch signaling activation (10).  
1.3.4. Lung cancer 
1.3.4.1. Non-small lung cancer 
  Non small cell lung carcinomas (NSCLC) account for approximately 85% of 
all lung cancers. It was shown that alterations of the Notch pathway are frequent in this 
kind of lung cancer. Decrease of NUMB expression and gain-of-function mutations of 
the Notch1 gene were observed. Also, the potential growth of NSCLCs depends on 
Notch signaling (90). It was proven that MRK-003 (a chemical Notch inhibitor) induces 
apoptosis and reduces tumor growth in vivo in lung cancer cells. These results support 
the hypothesis that inhibition of Notch activation using a γ-secretase inhibitor represents 
a potential new approach for the targeted therapy of lung cancer (91). 
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1.3.4.2. Small cell lung cancer 
              Small cell lung cancer (SCLS) differs from non-small cell lung cancer in that 
this tumor grows more rapidly, spreads more quickly, and responds better to 
chemotherapy and radiation. In cultured SCLC cells, Notch signaling leads to                       
a major G1 cell cycle arrest related to p21waf/cip1 reduction, repression of hASH1, and 
induction of the downstream Ras signaling pathway. It was suggested that in the case of 
a highly proliferate hASH1-dependent NE neoplasm, Notch signaling activation can be 
related to growth arrest and reduction in neoplastic potential (92). 
1.4. The Notch signaling pathway in organ fibrosis 
1.4.1. Pulmonary fibrosis 
 Example for an involvement of the Notch system in lung fibrosis stems from 
some forms of drug-induced interstitial lung disease (ILD), such as those caused by 
A771726, the active metabolite of leflunomide, inhibits leflunomide dihydroorotate 
dehydrogenase (DHODH) and induces EMT via Notch dependent manners. In vivo, 
administration of leflunomide provokes bleomycin-induced EMT in the lung and 
augments bleomycin-induced pulmonary fibrosis. Treatment of A549 cells with the 
A771726 metabolite, results in upregulation of Jagged1, 2, Dll1 and Notch1, 3, 4 
mRNAs expression. Furthermore, the level of NICD1 in the nuclear extract was 
increased in the presence of the A771726 and this increase was suppressed by co 
treatment with the inhibitor of γ-secretase (DAPT) (95). 
1.4.2. Systemic sclerosis 
Systemic sclerosis (SSc) is a chronic fibrotic disease of unknown etiology. It 
affects the skin and several internal organs such as the lung, heart and kidneys (94). It 
was proven that the Notch pathway is activated in SSc and that inhibition of Notch 
signaling prevents the development of fibrosis in two dermal fibrosis models of 
inflammation (bleomycin) - dependent and inflammation independent (Tsk-1 mice) (95). 
The last observation suggests that stimulation of dermal fibroblasts with recombinant 
human Jag-1-Fc chimera results in an SSc-like phenotype. Also, major release of 
collagen and differentiation of resting fibroblasts into myofibroblasts was observed. 
Introduction 
 
 16 
Chemical inhibition of Notch signaling or knock-down of its components showed 
reduced collagen expression in SSc fibroblasts, but not in fibroblasts from healthy 
donors was proven (96). 
1.4.3. Tubulointerstitial fibrosis 
            Tubulointerstitial fibrosis (TIF) is a common factor in the development and 
progression of chronic kidney disease (97). It was shown that the Notch pathway is 
activated in patients with TIF and in mouse models of this disease. Expression of Notch 
in renal epithelial cells is sufficient to induce TIF. Genetic deletion of Notch, specific 
only to tubular epithelial cells, or chemical blockade of the Notch pathway had                      
a protective effect on animals with induced TIF. It was also confirmed that this effect 
was mediated by the canonical Notch pathway (via Rbpjκ) (98, 99). 
1.5. The Notch signaling pathway in lung development 
1.5.1. Notch inhibition 
Deletion of protein O-fucosyltransferase 1 (Pofut1/post-translation modifier of 
Notch receptor; 100) and Rbpjκ in the lung epithelium shows no influence on the distal 
airway differentiation, including formation of alveolar sacs, type I and type II cells 
(AECI and AECII) (101, 102). However, alveolar development is impaired in Lfng 
(Lunatic Fringe) mutant mice. Lfng enhances Notch receptor activation by Delta ligands 
and suppresses activation by Jagged ligands (103). The Lfng mice display very poor 
type I alveolar epithelial cell differentiation starting from the saccule phase of 
development and during later stages (104). 
1.5.2. Notch activation 
 Double transgenic mice with constitutive overexpression of NICD1 in AECII 
present normal size, branching and lobulation of the lung. However, when NICD1 was 
constitutively expressed in epithelial cells of the distal lung the differentiation of 
alveolar epithelial cell types was prevented (Figure 1.9.). The enlarged cysts have been 
observed instead of normal saccules, built of cells that were lacking markers of the 
alveolar epithelium but were expressing several markers of the proximal airway 
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epithelium. It is worth to notice that cysts occurred specifically in regions of lung where 
NICD1 was overexpressed (105).   
 
 
 
 
Figure 1.9. Model of Notch action in mouse lung development. 
For the proper alveolar development a down-regulation of Notch is required. Constitutive expression of 
NICD resolves in appearing of a dilated cystic epithelium (modified from 105). 
 
Additionally, the effect of an expression of Notch3 in the peripheral epithelium 
was also investigated. In the developing lung, altered lung morphology and delayed 
development, leading to early lethality was observed. Similar to double transgenic, 
SPC-Cre; NICD1 mice, the inhibition of AEC type II into AEC type I transition was 
observed in constitutive SPC-NICD3 overexpressing mice. Furthermore, in the lungs of 
those animals metaplasia of undifferentiated respiratory cells was observed (106).  
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2. Aim of the study 
It is increasingly anticipated that the alveolar epithelial cells play a central role in 
the pathogenesis of idiopathic pulmonary fibrosis. Because of possibly persistent 
endogenous triggers and exogenous secondary hits, a permanent repair of the alveolar 
epithelium is necessary. Developmental pathways (such as TGFβ and Wnt signaling) 
have previously been confirmed to play a role in the pathogenesis and progression of 
IPF. The Notch signaling pathway, being known to be involved in cell fate decisions, 
differentiation and proliferation during development, may represent another 
developmental pathway involved in this disease. However, until now, there are no 
detailed reports with regard to regulation of the Notch pathway in idiopathic pulmonary 
fibrosis and the influence of Notch on alveolar epithelial proliferation and apoptosis. 
 
In this context, the aim of this thesis was to: 
 
1.  analyze the cellular regulation of the Notch signaling pathway (including the Notch 
receptors and ligands) on a mRNA, protein and immunohistochemical level in the 
lungs of IPF patients and bleomycin-challenged mice vs. the respective controls 
2. characterize the impact of the Notch signaling pathway on  proliferation and 
apoptosis of alveolar epithelial cells employing in vitro activation or inhibition 
strategies 
3. elucidate the downstream signaling pathway underlying the regulation of 
proliferation by the Notch system in mouse alveolar epithelial cells 
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3. Materials and methods 
3.1. Materials 
3.1.1. Equipment 
 
 Name                                                             Company 
 
Bacteria culture incubator Heraeus, Germany 
Cell Culture Incubator,Hera Cell Heraeus, Germany 
Electrophoresis Chambers Bio-Rad, UK 
Falcon tubes Greiner, Germany 
Film Casette Kodak, USA 
Filter Tips: 10; 100; 1000µl Eppendorf, Germany 
Filter units 0.22 µm syringe-driven 
Falcons filters: 70 µm; 40 µm; 10 µm 
Millipore, USA 
BD Falcon, USA 
Fluorescence and light microscope Leica, Germany 
Freezer +4°C Bosch, Germany 
Freezer -20 °C Bosh, Germany 
Frezer -80°C Bosh, Germany 
Whatmann paper Amersham Biosciences, UK 
Glass bottles: 250, 500, 1000 ml  Roth, Germany 
Glass Pipetes Greiner, Germany 
Light microscope LEICA,Germany  
Mini spin centrifuge VWR, Germany 
Mirax scanner Zeiss, USA 
Multifuge centrifuge Heraeus, Germany 
NanoDrop PeqLab, Germany 
PCR-thermocycler Bio-Rad, Germany 
Petri Dish Greiner, Germany 
Pipetboy Eppendorf, Germany 
Pipet tips: P10, P20, P100, P200, P1000 Nerbe plus, Germany  
Pipets Eppendorf, Germany 
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Precellys Homogeniser PeqLab, Germany 
Radiographic film Amersham Biosciences, UK 
Serological pipette: 5, 10, 25ml BD Falcon, USA 
Tissue Culture Chamber Slides BD Falcon, USA 
Tissue Culture Dish 100mm Greiner, Germany 
Tissue culture plates: 6, 24, 48 well BD Falcon, USA 
Vortex machine VWR, Germany 
Water bath  Medingen, Germany 
Western blot unit Bio-Rad, Germany 
3.1.2. Reagents 
 
 Name                                                                Company 
 
2-(-4-2-hydroxyethyl)-piperazinyl-1-ethansulfonate 
 
(HEPES) Sigma-Aldrich, Germany 
2-mercapto-ethanol Sigma-Aldrich, Germany 
Acetic acid Sigma-Aldrich, Germany 
Acetone Fluka Germany 
Acrylamide solution, Rotiphorese gel 30 Roth, Germany 
Agarose Roth, Germany 
Albumine, bovine serum Sigma-Aldrich, Germany 
Ammonium chloride Sigma-Aldrich, Germany 
Ammonium persulfate Sigma-Aldrich, Germany 
Ampicillin sodium Sigma-Aldrich, Germany 
BCATM Protein Assay Kit  Thermo Scientific, USA 
β-estradiol Sigma-Aldrich, Germany 
β-mercaptoethanol Sigma-Aldrich, Germany 
Bromophenol blue Sigma-Aldrich, Germany 
Calcium chloride Sigma-Aldrich, Germany 
EDTA-free Protease inhibitor Roche, Germany 
D-(+)-Glucose Roth, Germany 
Dharma FECT1 Thermo Scientific, USA 
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Dimethyl Sulfoxide Sigma-Aldrich, Germany 
Dispase BD Bioscience, USA 
DMEM medium Gibco, Germany 
DMEM-F12 medium Gibco, Germany 
DNA ladder Eurogentee, Belgium 
Dnase Fermentas, Germany 
Dulbecco’s phosphate buffered saline 1× PAA, Austria 
Amersham ECL™ Western Blotting Detection 
Kit 
Amersham Biosciences 
Ethanol absolut Fluka, Germany 
Ethidium bromide Sigma-Aldrich, Germany 
Ethylenediamine-tetraacetic acid (EDTA) Sigma-Aldrich, Germany 
Fetal calf serum (FCS) Roth, Germany 
Formaldehyde Roth, Germany 
Gel extraction kit Qiagen,  Germany 
Glycerol Roth, Germany 
Glycine Roth, Germany 
Glecergel Mounting Medium Dako, Denmark 
Heparin Ratiopharm, Germany 
Hydrochloric Acid Sigma-Aldrich, Germany 
Hydrocortisone Sigma-Aldrich, Germany 
ITS PAN Biotech, Germany 
iQ SYBR Green Supermix Kit Bio-Rad, Germany 
Kanamycin Roth, Germany 
Ketamin 10% Betapharm, Germay 
KOD Hot Start DNA polymerase Merck, Germany 
L-Glutamine Gibco, Germany 
Lipofectamine Invitrogen, Germany 
Magnesium chloride (anhydrous) Sigma-Aldrich, Germany 
Methanol Fluka, Germany 
Milk powder Roth, Germany 
Gel Extraction Kit Qiagen,  Germany 
N,N,N',N'-Tetramethyl-1-,2-diaminomethane  
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(TEMED) Sigma-Aldrich, Germany 
Oligo(dT) Applied Biosystem, USA 
Omniscript RT Kit Qiagen, Germany 
Opti-MEM medium Invitrogen, Germany 
Penicillin-Streptomycin PAA, Austria 
Plasmid isolation kit Qiagen, Germany 
Potassium chloride Roth, Germany 
Potassium phosphate monobasic Sigma-Aldrich, Germany 
PageRuler Prestained Protein Ladder  Fermentas, Germany 
Plasmid Mini and Maxi System Qiagen, Germany 
PMSF (phenylmethylsulfonyl fluoride) Thermo Scientific, USA 
Restriction endonucleases NEB, USA 
Restore Western Blot Stripping Buffer Thermo Scientific, USA 
RNAse inhibitor Applied Biosystems, USA 
RNeasy Mini Kit Qiagen, Germany 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, Germany 
Sodium acetate Sigma-Aldrich, Germany 
Sodium chloride Sigma-Aldrich, Germany 
Sodium citrate tribasic dehydrate Sigma-Aldrich, Germany 
Sodium hydroxide Sigma-Aldrich, Germany 
Sodium phosphate (monobasic, anhydrous) Sigma-Aldrich, Germany 
Streptavidin coated magnetic beads Invitrogen, Germany 
T4 DNA ligase Promega , USA 
TEMED Sigma-Aldrich, Germany 
TOP 10, competent cells Invitrogen, Germany 
Tris Roth, Germany 
Triton X-100 Sigma-Aldrich, Germany 
Trepan Blue Sigma-Aldrich, Germany 
Trypsin/EDTA PAA, Austria 
Tween 20 Sigma-Aldrich, Germany 
Vectashield mounting medium with DAPI Vector Labolarories, USA 
Xylazin 2% Ceva, France 
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3.2. Animal tissues  
All animal studies were performed in accordance with the guidelines of the Ethic 
Committee of the University of Giessen School of Medicine and approved by the local 
authorities (Regierungspräsidium Giessen, no. GI20/10-109/2011). Male and female 
mice (C57BL/6 strain) weighing between 18-20g were used in all experiments. Mice 
were obtained from Charles River Laboratories, Sulzfeld, Germany. The animals were 
anaesthetized with isoflurane (Isofluran, Baxter). Bleomycin (Hexal) in a dose of 5U/kg 
body weight was given as aerosol. The animals were orotracheally intubated and 
mechanically ventilated. A microsprayer (Penn-Century Inc, USA) was filled with 
200µl of saline solution containing bleomycin or a 0,9% saline for control mice. For the 
sample preparation the left main bronchus was clamped and the right lung was washed 
(lavaged) three times with 350µl 0.9% NaCl each time. The clamp from the left main 
bronchus was removed and fixed to the right main bronchus. The bronchus was cut 
distal from the clamp and the right lung was excised and shock frozen. Before taking 
the left lung for histology, the lung was flushed to clear it from blood via the right 
ventricle. Formalin fixation was achieved by filling the lung with 4.5% formaldehyde 
solution. Following instillation the lung was carefully removed and transferred into                  
a cup with formaldehyde. After overnight incubation at room temperature, the lung was 
transferred into an embedding cassette and stored in PBS at 4°C. This lung tissue was 
processed in a tissue processor (Leica, ASP 300s) for dehydration and then embedded in 
paraffin. 3µm thin sections were cut with a microtome for further analysis. 
3.3. Human tissues 
          The study was approved by the local research ethics committee, and written 
consent was obtained from all participants (no. 31/93, 84/93, 94/95, 29/01, 10/6, 
111/08). Lung tissue samples were obtained from twelve patients with IPF (mean age 
56 ± 8 years; four females, eight males) and ten control subjects (mean age 40 ± 4 years; 
five females, five males). Tissue samples were shock frozen or transferred into a cup 
with formaldehyde solution. After incubation at 4°C, the lung was transferred into an 
embedding cassette, buffered in PBS and stored at 4°C. This lung tissue was processed 
in a tissue processor (Leica, ASP 300s) Vacuum-dryer for dehydration and then 
embedded in paraffin. 3µm thin sections were cut with a microtome for further analysis. 
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3.4. Methods 
3.4.1. Mammalian cell culture 
3.4.1.1. MLE 12 cells 
The mouse lung epithelial cell line (MLE 12) (CRL-2110 ATCC; Manassas, 
VA, USA) were grown in 10cm2 tissue culture plates in DMEM/F12 medium, 
supplemented with 2% fetal bovine serum, insulin 0.005mg/ml, transferrin 0.01mg/ml, 
sodium selenite 30nM, hydrocortisone 10nM, beta-estradiol 10nM and HEPES 10mM 
in 95% air; carbon dioxide (CO2), 5%. The cell line was passage when reached 80-90% 
confluence. During passage, cells were incubated with 3 ml of trypsin solution for 3min 
at 37°C, after which 10ml of culture medium was added to neutralize enzymatic activity 
of trypsin. MLE 12 cells were diluted 1:15 with medium and passage to a new tissue 
culture plates.  
3.4.1.2. Isolation of alveolar epithelial type II cells (AECII) 
   Type II alveolar epithelial cells were isolated from the lungs of C57BL/6         
mice. Animals were anesthetized by intraperitoneal injection of                                         
a mixture of ketamine, xylazine and heparin (in the ratio 2:2:1). The abdominal cavity 
was opened and the renal artery was severed to exsanguinate the mouse. The lungs were 
perfused with 10ml of saline, until visually cleared of blood. Dispase, followed by 
0.5ml of 1% low-melting-point agarose in DMEM medium, was injected into lungs via 
the trachea (cannulated with a Vasofix® Safety, Braun). Agarose solution was allowed 
to solidify for 2min. Then lungs were separated from the trachea and other connective 
tissues. The isolated organ was incubated in 2ml of dispase for 45min at room 
temperature. After this time lungs were dissected in 7ml of Plus Medium. Lungs were 
chopped; the resulting crude cell mixture was incubated for 10min at room temperature 
with gentle shaking. This was followed by subsequent washes with Plus Medium and 
filtration through 70µm, 40µm and 10µm Nitex filters. The resulting filtrate was 
centrifuged at 130xg at 4°C for 10min and resuspended in 2mL of ER Lysis Buffer. The 
lysis reaction was stopped by adding Minus Medium + 10%FCS followed by 
centrifugation at 130xg at 4°C for 10min. Obtained cells were counted with Trypan 
Blue. The following antibodies (BD Bioscience) were then added to the cell suspended 
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in 5ml of Minus media + 10%FCS: anti-CD16/32 at 0.75µl/million cells, anti-CD45 at 
0,9µl/million cells, anti CD-31 at 0,4µl/million cells. Mix was incubated at 37°C for 
30min, then centrifuge and resuspende in Minus media (216µl/million cells). 
Streptavidin coated magnetic beads were prepared by washing three times in PBS and 
beads suspension (11µl/milion cells) was added to cells. The mix was incubated at room 
temperature for 30min and then placed on a magnetic separator for another 15min. Cell 
suspension was carefully aspirated from beads, transferred to a new tube and 
centrifuged as described above. Cells were then resuspended in Minus medium. Freshly 
isolated cells were immunocytochemically tested for purity percentage by using Pro-
SPC and Fibronectin staining. The AECII pneumocytes were plated either on 48 
wells/plate (150,000/well) or cytospin preparation was done (80,000 cells). Cells were 
grown in Minus Medium supplemented with 1% FCS. In this study only AECII cells up 
to day 3 were used. All cultures were maintained in humidified atmosphere with               
5% CO2 at 37°C. 
 
Minus medium Plus Medium ER (Erythrocyte) Lysis 
Buffer 
 
500ml D-MEM 
10mM HEPES 
1% Pen-strep 
 
 
Minus Medium 
supplemented with 
0.04mg/ml DNase 
 
8,29g NH4Cl 
1g KHCO3 
0,037g Na2EDTA x H2O 
Add 1000,0 dest. H2O 
pH 7,4 
3.4.2. RNA isolation and quantification 
Isolation of RNA from cultured cells was performed according to the 
manufacturer’s instructions provided with Rneasy Mini Kit (Qiagen). By applying           
2µl of the sample to a Nanodrop® spectrophotometer the concentration and absorbance 
(260nm and 280nm) of isolated RNA was measured.  
3.4.3. Reverse transcription 
             For the preparation of cDNA, 1µg RNA per sample was used. RNA was copied 
to cDNA using Omnitranscript RT Kit (Qiagen) and oligo dT (Applied Biosystem).  
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Reaction mix was prepared as shown: 
Components Volume/concentration 
                 10x Buffer 2µl 
                    dNTPs 2µl 
                  Oligo dT 1µl 
            RNase-inhibitor 0.5µl 
                        RT 1µl 
RNA up to 1µg 
H20 up to 20µl 
 
cDNA synthesis was achieved by incubating the mix at room temperature for 15min and 
then at 37°C for 1 hour. The resulting complementary DNA (cDNA) was further stored 
at -20°C. 
3.4.4. Real time PCR 
            Quantitative Real-time PCR is used to quantify and amplify specific sequences 
of DNA. After each amplification round, the DNA is quantified. Quantification is 
performed by means of fluorescent dye – SYBR® Green I – that directly binds to 
double-stranded DNA. The bound dye generates a signal that is proportional to the 
DNA concentration. Reactions were performed according to the manufacturer’s 
instructions provided with an iQ SYBR Green Supermix Kit (Bio-Rad).  
PCR reaction mix was prepared as shown: 
 
Components Volume/concentration 
iQ SYBR Green Supermix Kit 12,5µl 
Forward primer 0,4µl 
Reverse primer 0,4µl 
cDNA 25-50µg 
H20 up to 25µl 
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Cycling conditions were: 95°C for 3min, followed by 40 cycles of 95°C for 10s, 60°C 
for 30s, 1 cycle 95°C for 1min, 55°C for 1min and 71 cycles of 60°C for 10s. Melting 
curve analysis was performed to confirm the exclusive amplification of the expected 
PCR product. 
 
GENE BANK  
ACESSION 
NUMBER 
FORWARD PRIMER (5’-3’) REVERSE PRIMER (5’-3’) 
Notch1 mouse 
NM_008714.3 atggcttcgactgccagctcac tcggcactgttacagccctggt 
Notch2 mouse 
NM_010928.2 gggcagctgctgtcaataat tttggccgcttcataacttc 
Notch3 mouse 
NM_008716.2 caggccacgtgtcttgaccgaa 
tgggctgctctgacattcgtcg 
 
Notch4 mouse 
NM_010929.2 tctggatgtggacacctgtggacc 
tctctgtggactagccccagtcgt 
 
Dll1 mouse 
NM_007865.3 gccttcagcaaccccat tgttgcgaggtcatcgg 
Dll4 mouse 
NM_019454.3 tgcctgggaagtatcctcac tagagtccctgggagagcaa 
Jagged1 mouse 
NM_013822.5 actgggcctgacaaatacca tgaggaggtctccttgcag 
Jagged2 mouse 
NM_010588.2 gcctcctcctgctgctttgtga atcaggctgctgtcaggcaggt 
Hes1 mouse 
NM_008235.2 ctgcagcgggcgcagatgac acacgtggacaggaagcggg 
Hey1 mouse 
NM_010423.2 ccacgctccgccaccatgaa cggcgcttctcgatgatgcct 
Hey2 mouse 
NM_013904 tcgcgatgaagcgcccttgt tcactgagcttgtagcgtgcc 
β-actin mouse 
NM_007393 ctacagcttcaccaccacag ctcgttgccaatagtgatgac 
Notch1 human 
NM_017617.3 atggacgtcaatgtccgc ccctggtagatgaagtcgga 
Notch2 human 
NM_024408.3 catggccaatagcaatcctt tcacaacgaggtcctgcata 
Notch3 human 
NM_000435.2 ccgatgtcaacgagtgtctg aatgtccacctcgcaatagg 
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Notch4 human 
NM_004557.3 gaccagaaagacaaggccaa aacccacgtcacacacacat 
DLL1 human 
NM_005618.3 gaatctgtgtggagagcttcaat gtcgactccttcagtctgcc 
DLL4 human 
NM_019074.3 tctgacccacagctagggag tctcgctcatcatcgaagc 
Jagged1 human 
NM_000214.2 caagtgccaccgtttctaca agtcgggaggcaaattcac 
Jagged2 human 
NM_145159.1 gatcccggagcaaatgg ggccacctggacaataactg 
β-actin human 
NM_007393 acagagcctcgcctttgccg acatgccggagccgttgtcg 
 
Table 1. List of primers used for Real time PCR. 
 
The primers used for qPCR were designed with the help of the online program Primer-
BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). All primer sequences are 
listed in Table 1. A β-actin gene was used as the reference gene in all quantitative Real 
time PCR reactions. The relative transcript abundance of a gene was presented as              
∆Ct values (∆Ct = Ct reference – Ct target).  
3.4.5. Protein isolation and quantification 
Harvested cells and frozen lung homogenate specimen were lysed in lysis buffer, 
which contained a protease inhibitor cocktail and PMSF. Lysates were incubated on ice 
for 30min, followed by centrifugation 12000rpm for 10min at 4ºC. Supernatants were 
stored in -80°C. Quantification of protein was performed using BCATM Protein Assay 
Kit (Pierce) according to the manufacturer’s instructions. As a standard different bovine 
serum albumin (BSA) concentrations were used. 
 
Lysis buffer: 
50mM Tris 
50mM NaCl 
5mM EDTA 
1%  Triton X-100 
0.5% Sodium deoxycholat 
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3.4.6. SDS polyacrylamide gel electrophoresis  
The denaturating SDS polyacrylamid gel electrophoresis (SDS-PAGE) was used 
to separate proteins electrophoretically according to their molecular weight. Protein 
sample from tissue or cells were reduced (by adding 10% β-mercaptoethanol) and 
boiled for 10min in 4 x loading buffer and then cooled on ice for 5min. The samples 
were vortexed and collected by brief centrifugation. This mix was loaded into the SDS 
acrylamide gel and in the presence of 1 x electrode buffer, the electrophoresis was 
performed at 100V. 
 
Separating Gel, 10ml 
 8% 10% 15% 
A.dest. 3,87ml 3,2 ml 1,53ml 
1,125M Tris, pH 8,8 3,33ml 3,33ml 3,33ml 
Acylamide/Bisacrylamide 
(30%/0,8%) 
2,66ml 3,33ml 5,0ml 
10% SDS 100µl 100µl 100µl 
TEMED 10µl 10µl 10µl 
10% APS 50µl 50µl 50µl 
 
 
 
Stacking Gel, 10 ml 
A.dest. 6,57ml 
0,625M Tris, pH 6,8 2,0ml 
Acylamide/Bisacrylamide 
(30%/0,8%) 
1,33ml 
10% SDS 100µl 
TEMED 10µl 
10% APS 100µl 
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4 x Loading buffer: 
 
Electrode buffer 10x: 
5g SDS 30g Tris 
25ml 0,625M Tris-HCl pH 6.8 144g Glycine 
40ml Glycerol 10g SDS 
0,0005g Bromphenolblue Add dest. H20 to 1000ml 
Add dest. H20 to 100ml  
 
3.4.7. Protein blotting  
Proteins separated on the SDS poly-acrylamide gel were transferred into PVDF 
membrane (Amersham) using the semi-dry technique in a transfer buffer. 
 
 
Transfer buffer: 
4,85g Tris 
22,51g Glycine 
400ml MeOH 
Add dest. H2O to 2000 ml 
3.4.8. Protein detection  
            PVDF membranes with transferred proteins were blocked in 5% non-fat dry 
milk in TBST for 2h at room temperature. After blocking, membranes were incubated at 
4°C overnight with one of the antibodies listed in Table 2. The next day, membranes 
were washed 3 x 10min/TBST buffer and were incubated for 1h with HRP-conjugated 
secondary antibody (Dako) and next washed again with TBST buffer. Proteins on the 
membrane were detected using ECL Western Blotting Reagent (Amersham), according 
to the manufacturer’s instructions provided with the kit. In order to re-probe membranes 
with β-actin or another antibody, membranes were stripped for 15min in commercially 
available Stripping Buffer (Pierce) and used once more for protein detection. 
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TBST (pH 7,6) 10x: 
48,6g Tris 
116g NaCl 
20ml Tween 20 
Add dest. H2O to 2000,0 
 
 
 
Species 
Name Source Dilution 
Human Mouse 
Company 
Rabbit 1:700 - X Abcam 
NICD1 
Sheep 1:600 X - R&D Systems 
NICD2 Rabbit 1:1000 X X Abcam 
NICD3 Rabbit 1:1000 X X Abcam 
Rabbit 1:500 - X Sigma-Aldrich  
NICD4 
 
Mouse 1:1000 X - Cell Signaling 
Delta1 Goat 1:1000 X X R&D Systems 
Rabbit 1:750 - X Cell Signaling 
Delta3 
Mouse 1:500 X - R&D Systems 
Delta4 Goat 1:750 - X R&D Systems 
Jagged1 Rabbit 1:300 X - Santa Cruz 
Hes1 Goat 1:500 X - R&D Systems 
PCNA Rabbit 1:1500 - X Abcam 
Cl.caspase-3 Rabbit 1:500 - X Trevigen 
Rabbit 1:4000 - X Abcam 
 
β-actin Mouse 1:4000 X - Abcam 
    Table 2. List of primary antibodies used in Western Blot. 
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3.4.9. Densitometry  
             Protein densitometry was measured using AlphaEaseFC software. β-actin served as 
a loading control. 
3.4.10. Immunohistochemistry  
              To localize and assess the expression of particular proteins in human and 
mouse lung sections, immunohistochemical analysis was performed using                      
a standardized streptavidin-biotin systems kit according to the manufacturer’s 
instructions (ZytoChem Plus AP Kit, Broad Spektrum and ZytoChem Plus HRP Kit, 
Broad Spektrum, Zytomed). Paraffin-embedded, formalin-fixed lung tissue was 
sectioned and used for immunohistochemical analysis. The antibodies from Table 3 
were used. Sections were deparaffinized at 60oC for 1h and then 10min in xylene. After 
dehydration, using a stepwise decrease in ethanol concentration gradient 
(99.6%>96%>80%>70%>50%), sections were washed in 1x PBS. Antigen retrieval was 
performed in citrate buffer (pH 6.0) for 20min at 100°C. Slides were washed three times 
for 5min in 1 × PBS. Counterstaining was performed with haemalaun for 2min followed 
by washing the slides under running tap water, which resulted in blue nuclei. Sections 
were then mounted with a glycerol mounting medium (Dako), allowed to dry and 
evaluated by usage of a MIRAX scanner. Negative controls were obtained in all cases 
by omitting the primary antibody.  
 
         PBS (pH 7,4) 10x: 
                        80g NaCl 
                  2g KCl 
            14,4g Na2HPO4 
               2,4g KH2PO4 
       Add dest. H2O to 1000ml 
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Species 
Name Source Dilution 
Human Mouse 
Company 
NICD1 Rabbit 1:200 X X Abcam 
Rabbit 1:150 - X Rockland 
DLL1 
Rabbit 1:100 X - Abcam 
Hes1 Goat 1:50 X - R&D Systems 
Pro -SPC Rabbit 1:750 X X Millipore 
Fibronectin Rabbit 1:250 X - Abcam 
Ki67 Rabbit 1:400 X - Sigma-Aldrich 
   Table 3. List of primary antibodies used in Immunohistochemistry. 
3.4.11. Immunocytochemistry  
               Immunocytochemistry method was performed to localize specific proteins in 
the cell. Cells were seeded or in 8-well chamber slides (MLE 12) or cytospin 
preparation was used (AECII). Cells were fixed with 4% paraformaldehyde for 10min, 
permeabilized with 0.2% Triton X-100. After washing 3 x 10min with PBS, cells were 
blocked in 5% BSA in PBS for 1h at room temperature and then incubated with the 
appropriate primary antibody (Table 4.) overnight at 4°C. After washing 3 x 10min with 
PBS and 1h incubation with a secondary antibody (Invitrogen), slides were mounted 
with Vectashield mounting medium with DAPI (4',6-diamidyno-2-fenyloindol) 
(VectorLab). Controls were performed omitting the primary antibody. Visualization of 
protein localization was performed using a Leica DMR microscope and photographed 
using MetaMorph 7.0 software. 
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Species 
Name Source Dilution 
Human Mouse 
Company 
NICD1 Rabbit 1:1000 - X Abcam 
Pro-SPC Rabbit 1:1250 - X Millipore 
E-cadherin Rabbit 1:400 - X Cell Signaling 
α-SMA Rabbit 1:200 - X Abcam 
Fibronectin Rabbit 1:200 - X Abcam 
Ki67 Rabbit 1:500 - X Abcam 
    
  Table 4. List of primary antibodies used in Immunocytochemistry. 
 
3.4.12. Cloning of the mouse intracellular Notch1 receptor 
3.4.12.1. PCR product purification 
                 To subclone the intracellular Notch1 gene into an expression vector, the 
DNA template was analyzed for the appropriate restriction sites (NheI and XmaI) using 
the NEBcutter 2.0 software and appropriate primers were designed. Cleaved Notch1 
cDNA was amplified from total lung RNA by PCR (with KOD Hot start polymerase, 
Merck) using the forward and reverse primers 5´- CGT GGC TCC ATT GTC TAC CT-
3´ and 5´- CAC ACA GGG AAC TTC ACC CT-3´, respectively. Restriction sites, 
Kozak sequence and ATG codon was added to the amplified product by PCR using the 
forward and reverse primers 5´- GCC ACC ATG TCC CGC AAG C-3´, 5´- GCT AGC 
GCC ACC ATG TCC-3´ and 5´- CCC GGG TTA TTT AAA TGC CTC TGG-3´, 
respectively. The created DNA fragment was analyzed and separated by agarose gel 
electrophoresis, excised and gel-purified using a commercially available QIAquick Gel 
Extraction Kit (Qiagen) according to the manufacturer’s protocol.   
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3.4.12.2. Ligation of PCR products into the pGEM-T Easy vector 
  
                 The purified PCR product was ligated into pGEM-T Easy vector (Promega) 
using the ligation mix presented above.   
 
Components Volume/concentration 
Ligase 10x Buffer 1µl 
pGEMT-T Easy Vector (50ng) 100ng 
Purified PCR product 17ng 
T4 DNA ligase 1U 
Autoclaved, deionized water up to 10µl 
This reaction mix was incubated overnight at 16°C.    
 
3.4.12.3. Transformation and amplification of plasmid 
                 After ligation, plasmids were transformed in competent E. coli TOP10 cells 
(Invitrogen) for further amplification. Up to 100ng were added into a vial of One Shot® 
cells and mixed gently. Samples were incubated on ice for 30min and then the cells 
were heat-shocked for 30s at 42°C, without shaking, and placed on ice for 2min. 
Aseptically, 250µl of pre-warmed S.O.C. medium (Invitrogen) were added to each vial 
and shaken at 37°C for 1h at 225 rpm. Afterwards 100µl of cells from each 
transformation were spread on a pre-warmed selective plate (X-Gal and IPTG were 
added to the LB medium) and incubate overnight at 37°C. After overnight incubation, 
individual bacterial colonies were picked from the plate on the following day and 
inoculated in LB medium containing the appropriate antibiotics. The bacterial tubes 
were shaken overnight at 37°C at 225rpm. Plasmids were subsequently isolated using           
a Qiagen plasmid isolation kit. 
 
3.4.12.4. Subcloning into the mammalian expression vector 
                 In order to subclone NICD1 from pGEM-T Easy vector into a mammalian 
expression vector, pIRES-DsRed2, both the empty expression vector and pGEM-T Easy 
plasmid, containing the mouse NICD1 PCR product, were digested with the same 
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restriction enzymes for 1-3h at 37°C, separated by agarose gel electrophorsis and gel-
purified. The purified PCR product and the linearized purified vector were ligated as 
described in the previous chapter 3.4.12.2. The following steps were also performed as 
described in the previous chapter 3.4.12.3. The intracellular Notch1 construct was 
verified by sequencing. 
3.4.13. Transient plasmid DNA transfection 
               Transient transfection of plasmids is a technique to transfer DNA into 
eukaryotic cells. In this method transfected DNA is not integrated into the host genome. 
NICD1 was transiently transfected into MLE 12 cell reagent using 
LipofectamineTM2000 (Invitrogen) according to the manufacturer's instruction. Briefly, 
Lipofectamine and NICD1 plasmid were added separately to OptiMEM, mixed and 
incubated at room temperature for 5min. NICD1 and Lipofectamine were incubated 
together for another 20min at room temperature and were added to the cells next. 
3.4.14. Antisense Oligonucleotides 
              The siRNA oligonucleotides specific to mouse POFUT1 mRNA (D-059834-01 
siRNA) were obtained from Thermo Scientific. MLE 12 cells were transiently 
transfected with 60nM POFUT1 siRNA or non-specific siRNA using                               
a DharmaFECT1 reagent (Thermo Scientific). Briefly, DharmaFECT1 was added to 
OptiMEM medium and incubated for 5min. siPOFUT1 or non-specific siRNA was 
added to OptiMEM and transferred into DharmaFECT1 and OptiMEM mix, after 5min 
of incubation. The siRNA and DharmaFECT1 mix was incubated for another 20min at 
room temperature, followed by addition of the complete medium without antibiotics. 
Prepared solution was added directly to the cells. 
3.4.15. Proliferation assay 
               The primary, mouse alveolar epithelial type 2 cells (AECII) or MLE 12 cells 
were grown in 48-well plates in low serum DMEM medium and then stimulated with                 
a γ-secretase inhibitor, 10µM DAPT (Tocris) for 54h. MLE 12 cells were additionally 
transfected with NICD1 plasmid or POFUT1 siRNA. After 24-72h the cells were 
exposed to [3H]Thymidine (0.2µCi per well, PerkinElmer) for 6-12h, rinsed three times 
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with PBS and solubilized with 0.2ml 0.5M sodium hydroxide; 0.1ml of the solubilized 
material was quantified by liquid scintillation counting (TRI-CARB® 1500, A Canbera 
Company, USA). 
3.4.16. Cell death assay 
               To quantified cell death of MLE 12 cells LDH assay was performed according 
to the manufacturer's instruction. Mainly, LDH assay is based on lactate dehydragenase 
(LDH) which is a stable enzyme, present in all cell types and rapidly released into the 
cell culture medium upon damage of the plasma membrane. Briefly, cells were 
stimulated with a γ-secretase inhibitor, 10µM DAPT (Tocris) for 54h, transiently 
transfected with NICD1 plasmid (24h) or POFUT1 siRNA (72h) and stimulated with 
the apoptosis inducer staurosporine 1mg/ml (Sigma-Aldrich) for 5h.  
3.4.17. Microarray experiments 
              Lung tissues were collected from patients with interstitial lung disease 
undergoing lung transplantation at the Universities of Giessen (Germany) or Vienna 
(Austria). All patients were accessed, diagnosed, and treated in expert centers for 
interstitial lung disease. Nontransplanted donor lung tissue showing no evidence of 
interstitial lung disease served as healthy controls. Laser-Microdissection of donor and 
patient lungs was performed as described previously (107). Cryosections from lung 
tissue were mounted on glass slides. After short haemalaun staining, septa were 
microdissected under optical control using the Laser Microbeam System (P.A.L.M.). 
IPF and donor samples were competitively hybridized on Agilent whole human genome 
arrays (G4112A, Agilent). 
              Mouse lung epithelial cells (MLE 12) were transiently transfected with the 
pIRES dsRed2 NICD1 overexpressing vector or pIRES dsRd2 vector for 12h, 24h and 
48h, followed by the Agilent whole mouse genome array (G4122F, Agilent) analysis of 
RNA expression.  
              Briefly, RNA was isolated using the RNeasy kit (Qiagen) following the kit 
instructions. Total RNA was reverse-transcribed, preamplified, and labeled using          
the BD Atlas SMART Fluorescent Probe Amplification Kit (Clontech Laboratories). 
RNA was subjected to reverse transcription. cDNA obtained from the reverse 
transcription was amplified with 22 SMART PCR cycles. The dsDNA products were 
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labeled by four additional PCR cycles in the presence of aminoallylated UTP, and then 
coupled with monofunctional reactive Cy3- and Cy5-dyes (Amersham).                                     
The labeled dsDNA was purified with the Qiaquick PCR Purification Kit (Qiagen) 
following the kit instructions. After the purification procedure concentration, quality 
(RNA absorbance ratio measured at 260/280 nm) and degree of incorporation of 
fluorescent dyes (Cyanine 3-labeled and Cyanine 5-labeled concentration) was recorded 
by spectrophotometer (Agilent Bioanalyzer 2100). Samples were competitively 
hybridized on Agilent whole human genome arrays (G4112A) or Agilent whole mouse 
genome array (G4122F, Agilent) according to Agilent's protocol. After hybridization, 
slides were washed and afterwards scanned with the Axon 4100A (Molecular Devices, 
Munich, Germany).  
3.4.18. Statistical analysis of data 
              If not indicated differently, values are presented as mean ± SEM. The mean of 
indicated groups were compared using unpaired Student t-tests. A level of p<0.05 was 
considered statistically significant. NS, not significant 
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4. Results 
4.1. Identification of differently regulated pathways in septae 
from IPF vs. healthy organ donors  
             It is known that alveolar re-epithelialization appears disturbed in IPF. The 
reasons for the abnormal reactions of the alveolar epithelial cells (AECs) upon injury 
are unknown. Some of them may be the answer to the initial insult, whereas others may 
be the result of accelerated epithelial cell proliferation/migration (11). To investigate 
which developmental pathway may play a role in the epithelial regeneration response in 
IPF, microarray analysis was performed on microdissected septae and lung 
homogenates from IPF and organ donor lungs (Figure 4.1.). In microdissected septae 
from histological „normal” appearing areas of IPF lungs TGFβ, Wnt and Notch 
signaling pathways were formed to be differentially regulated when compared to septae 
of healthy organ donors. We assumed that septae isolated from those still “normal” 
appearing areas of the lung could represent early stages of the disease. In the “fibrotic” 
areas, representing the end-stage of disease vs. septae of healthy organ donors, mitogen-
activated protein kinase (MAPK), vascular endothelial growth factor (VEGF) and 
mTOR pathways were suggested to be differently regulated. On the level of lung 
homogenates only the mTOR pathway appeared to be differentially regulated                 
(Figure 4.1.). 
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Figure 4.1. Pathway analyses performed on a data obtained from a microarray experiments on 
microdissected septae and lung homogenates from IPF vs. healthy organ donors. 
 
4.2. Analysis of the Notch signaling pathway in lungs of 
patients with idiopathic pulmonary fibrosis 
4.2.1. Expression analysis of Notch receptors and ligands 
            To investigate potential changes in the levels of Notch signaling pathway 
elements in human lungs, mRNA and protein expression of Notch receptors and ligands 
was analyzed. mRNA and proteins were isolated from human lung homogenates of 
transplanted IPF and organ donors. The mRNA expression of Notch pathway elements 
were analyzed by Real-time PCR (Figure 4.2.A). We did not observed any significant 
differences in expression of analyzed genes in IPF compared to healthy donor samples. 
The protein levels of Notch receptors (Figure 4.2.B and C) and ligands (Figure 4.2.D 
and E) were determined by Western blot. No significant changes in the expression of 
Notch pathway elements were observed with the exception of the intracellular domain 
of Notch1 receptor (NICD1) and DLL1 which were found to be significantly increased 
in IPF vs. donor lungs (Figure 4.2.B-E). 
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Figure 4.2. Expression analysis of Notch receptors and ligands in lung homogenates of organ 
donors and IPF patients. 
(A) Real-time PCR analysis of Notch receptors and ligands in lung homogenates from organ donors and 
IPF patients. Given is the fold-increase in mRNA normalized to β-actin expression.                                        
(B) Expression of Notch receptors in lung homogenates was analysed by Western blot in lung 
homogenates from organ donors and IPF patients. β-actin served as a loading control.                                
(C) Densitometric analysis of Notch receptors, normalized to control. (D) Notch ligands expression was 
analysed by Western blot in lung homogenates from healthy donors and IPF patients. β-actin served as a 
loading control. (E) Densitometric analysis of Notch ligands, normalized to control. All values are given 
as mean ± SEM (n ≥ 6). Statistical significance was assured by Student’s t-test. Significance levels are 
indicated. 
 
4.2.2. Localization of NICD1 and DLL1 in the lungs of patients with 
idiopathic pulmonary fibrosis 
             To identify the cell-specific expression of NICD1 and DLL1, 
immunohistochemistry was performed on the sections obtained from IPF patients and 
organ donors. It was examined whether the expression was specifically localized to 
alveolar epithelial cells or/and mesenchymal cell type in the human lung                  
(Figure 4.3. and 4.4.). 
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Figure 4.3. Expression of NICD1 and DLL1 in AECII in lungs from organ donors and IPF patients. 
Immunohistochemical staining of NICD1 (A) and DLL1 (B) in paraffin-embedded, serial lung sections 
obtained from organ donors and IPF patients. Pro-SPC was used as a marker of AECII cells. The pictures 
are representative of at least five independent experiments. Bar size is indicated. 
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Figure 4.4. Absence of NICD1 and DLL1 in mesenchymal cells in lungs of organ donors and IPF 
patients. 
Immunohistochemical staining of NICD1 (A) and DLL1 (B) in paraffin-embedded lung sections obtained 
from donors and IPF patients. Fibronectin was used as a mesenchymal cell marker. The pictures are 
representative of at least three independent experiments. Bar size is indicated. 
 
As shown in Figure 4.3. and 4.4. the expression of NICD1 and DLL1 was increased in 
IPF sections compared to donor tissue. The strongest immunoreactivity of the NICD1 
receptor was observed in alveolar epithelial type 2 cells (AECII) but expression in other 
compartments (e.g. myofibroblasts, mucus cells) can not be excluded on the basis of the 
experiments conducted in this study. The specific signal of DLL1 protein on 
immunohistochemistry was observed almost exclusively in AECII. To verify if 
expression of NICD1 and DLL1 can be found in the same group of AECII in the 
fibrotic lung, immunohistochemistry on the serial sections was performed (Figure 4.5.). 
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Figure 4.5. Expression and colocalization of NICD1 and DLL1 in the same population of AECII in 
lung tissue of  IPF patients. 
Immunohistochemical staining of NICD1, DLL1 and Pro SP-C, as a marker of AECII, in paraffin-
embedded lung serial sections obtained from IPF patients. The pictures are representative of at least five 
independent experiments. Bar size is indicated. 
 
As shown in Figure 4.5. NICD1 and DLL1 are expressed in the same population of             
AECII cells in the fibrotic lung. It can also be noticed, that the activated Notch1 
receptor is not localized in nuclei of all AECII and that the DLL1 ligand is localized not 
only in cytoplasm but also in the nucleus. 
4.2.3. Expression analysis of the Notch target gene HES1 
            To further investigate not only the changes in the levels of Notch receptors and 
ligands in human lungs, but also the activation of this pathway, expression analysis of 
one of the Notch target genes, Hes1 was performed. The proteins were isolated from 
human lung homogenates of transplanted IPF patients and organ donors. The protein 
level of the Notch target gene Hes1 was determined by Western blot (Figure 4.6.). As 
expected, the protein level of Hes1 was significantly elevated in fibrotic samples. The 
expression of this protein in AECII was also confirmed in the distal lung epithelium in 
the human lung, as determined by IHC (Figure 4.7.).  
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Figure 4.6. Expression analysis of Hes1 in lung homogenates of organ donors and IPF patients. 
(A) Hes1 expression was analyzed by Western blot in lung homogenates from organ donors and IPF 
patients. β-actin served as a loading control (B) Densitometry analysis of the Hes1 protein expression 
level, normalized to control. All values are given as mean ± SEM (n ≥ 6). Statistical significance was 
assured by Student’s t-test. Significance levels are indicated. 
 
 
 
 
 
 
Figure 4.7. Expression of Hes1 in AECII in lungs of organ donors and IPF patients. 
Immunohistochemical staining of Hes1 in paraffin-embedded lung sections obtained from donors and IPF 
patients. Pro-SPC was used as an AECII marker. The pictures are representative of at least three 
independent experiments. Bar size is indicated. 
 
 
4.3. Analysis of the Notch signaling pathway elements in             
an experimental model of pulmonary fibrosis 
4.3.1. Expression of Notch signaling pathway elements in bleomycin- 
induced pulmonary fibrosis 
             To find out if the results obtained in human IPF lungs can be reproduced in an 
animal model of lung fibrosis, the mRNA and protein expression of Notch receptors and 
ligands was analyzed in the lung homogenates of bleomycin- challenged mice. No 
significant changes in the mRNA expression of Notch pathway elements were observed 
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with the exception of the Notch1 receptor at day 14 and day 28 and the Notch3 receptor 
at day 21 (post bleomycin application), which were found to be significantly decreased 
in lung homogenates of control vs. bleomycin- challenged mice (Figure 4.8.A). Also, 
mRNA of such ligands as Delta1 (Dll1) and Jagged2 were significantly decreased at 
day 14 and day 21 (post bleomycin application), respectively (Figure 4.9.A). 
               In addition, it was confirmed on the protein level that expression of NICD1 
was significantly upregulated from day 7 until day 21 post bleomycin                   
(Figure 4.8.B and C). In case of Dll1 ligand immunoblotting showed a similar 
upregulation at day 21 and 28 post bleomycin (Figure 4.9.B and C). Additionally, 
downregulation of the intracellular domain of Notch3 receptor and ligand Delta4 (Dll4) 
was observed at later time points (days 21 and 28) (Figure 4.9.B and C). 
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Figure 4.8. Expression analysis of Notch receptors in lung homogenates of control and bleomycin-
challenged mice. 
(A) Real-time PCR analysis of Notch receptors in lung homogenates from organs from control and 
bleomycin-challenged mice. Given is the fold-increase in mRNA normalized to β-actin expression.                  
(B) Notch receptor expression was analyzed by Western blot in lung homogenates from control and 
bleomycin-challenged mice. β-actin served as a loading control. (C) Densitometric analysis of Notch 
receptors, normalized to control. All values are given as mean ± SEM (n≥4).  
Statistical significance was assured by Student’s t-test. Significance levels are indicated. 
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Figure 4.9. Expression analysis of Notch ligands in lungs homogenates of control and bleomycin- 
challenged mice. 
(A) Real-time PCR analysis of Notch ligands in lung homogenates from organs from control and 
bleomycin-challenged mice. Given is the fold-increase in mRNA normalized to β-actin expression.              
(B) Notch ligand expression was analyzed by Western blot in lung homogenates from control and 
bleomycin-challenged mice. β-actin served as a loading control. (C) Densitometric analysis of Notch 
ligands, normalized to control. All values are given as mean ± SEM (n≥4).  
Statistical significance was assured by Student’s t-test. Significance levels are indicated. 
 
 
 
 
Dll1
control d7 d14 d21 d28
0
1
2
3
     ns
    ns
p=0.05
p=0.028
 
 
 
 
 
re
la
tiv
e
 
pr
o
te
in
 
ex
pr
e
s
si
o
n
Dll3
control d7 d14 d21 d28
0
1
2
ns
ns
ns
ns
 
 
 
 
re
la
tiv
e
 
pr
o
te
in
 
e
x
pr
e
s
s
io
n
A 
37 kDa 
control      d7    d14    d21    d28 
Bleomycin 
37 kDa β-actin 
37 kDa 
80 kDa Dll3  
β-actin 
 Dll4 
β-actin 
65 kDa 
70 kDa 
 Dll1 
B 
C 
 Dll4
control d7 d14 d21 d28
0.0
0.5
1.0
1.5
p=0.05
p=0.05
ns
ns
 
 
 
 
re
la
tiv
e
 
pr
o
te
in
 
e
x
pr
es
si
o
n
Dll1 Dll4 Jagged1 Jagged2
-11.75
-9.25
-6.75
-4.25
-1.75
control
d7
d14
d21
d28
    ns
     ns
    ns
    ns     ns
     ns
p=0.048
     ns
    ns
     ns
      ns
    ns
    ns
  p=0.01
    ns
ns
∆∆ ∆∆
Ct
Results 
 
 51 
4.3.2. NICD1 colocalization in the lungs of control and bleomycin- 
treated mice 
              Immunohistochemistry confirmed a strong expression of NICD1 in bleomycin-
injured lungs at day 14, compared to the weak signal observed in the lungs of saline 
treated mice (Figure 4.10.). By using serial sections, stained with the AECII specific 
marker pro SP-C, activated Notch1 was found to be almost exclusively colocalized in 
alveolar epithelial type II cells.      
 
 
 
Figure 4.10. Expression and colocalization of the NICD1 receptor in AECII in the lungs of control 
and bleomycin-treated mice. 
Immunohistochemical staining of NICD1 in paraffin-embedded lung sections obtained from saline and 
bleomycin-treated mice. The pictures are representative of at least four independent experiments. Bar size 
is indicated. 
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4.4. Influence of Notch signaling on epithelial proliferation  
          Notch1 has been known to play a major role in the proliferation of normal rat 
kidney tubule epithelium (NRK) cells. It has been proven, using in vivo studies, that 
genetic overexpression of Notch1 likely plays a role in tubulointerstitial fibrosis (TIF) 
development via controlling cell proliferation (5). As shown in 4.3. and 4.10. NICD1 is 
mostly expressed by AECII in IPF and in the bleomycin mouse model of pulmonary 
fibrosis. Therefore, primary epithelial mouse cells (AECII) and an alveolar epithelial 
cell line (MLE 12) were used for further studies, addressing the role of Notch on lung 
epithelial proliferation. 
4.4.1. Influence of NICD1 expression on proliferation of MLE 12 cells 
             To test whether NICD1 has a functional role in alveolar epithelial cells, the 
cDNA encoding exclusively the intracellular domain of Notch1 was cloned into the 
mammalian expression vector pIRES-DsRed2. 24h post transfection, MLE 12 cells 
showed a higher expression of NICD1 as compared to a control (empty) vector (Figure 
4.11.A.). As expected, the mRNA expression levels of Notch target genes Hes1, Hey1 
and Hey2 were significantly upregulated after 24h of NICD1 overexpression in MLE 12 
cells (Figure 4.11. B.). 
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Figure 4.11. Overexpression of the NICD1 receptor in MLE 12 cells. 
(A) Western blot of MLE 12 cells overexpressing the NICD1 receptor, 24h after transfection and 
compared to an empty vector. ß-actin served as a loading control (B) Real-time PCR analysis of Notch 
downstream genes: Hes1, Hey1, Hey2 in MLE 12 cells, 24h after transfection with the NICD1 
overexpressing vector compared to an empty vector. Given is the fold-increase in mRNA expression in 
response to transfection with an empty vector normalized for β-actin expression) vs. NICD1.                  
All values are given as mean ± SEM (n=3).  
Statistical significance was assured by the Student’s t-test. Significance levels are indicated.  
 
To measure the level of proliferation of epithelial cells in vitro, the [3H]-thymidine 
incorporation method was used. Increased cDNA synthesis, which indicated raised 
proliferation following 30h of Notch1 intracellular domain expression, was confirmed 
in MLE 12 cells (Figure 4.12.A.). Moreover, in Notch-expressing cells, increased 
protein expression of proliferating cell nuclear antigen (PCNA) was observed                
(Figure 4.12.B and C), which was consistent with Notch1-induced proliferation. 
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Figure 4.12. Cell proliferation in Notch-expressing MLE 12 cells. 
(A) [3H]-Thymidine incorporation measured in MLE 12 cells following 30h of Notch1 expression. All 
values are given as mean ± SEM (n ≥ 10) and are normalized to mock transfection (100%) as a control.             
(B) PCNA expression in MLE 12 cells following 30h of Notch expression. ß-actin served as a loading 
control. (C) Densitometric analysis of the PCNA protein expression level, normalized control.                 
All values are given as mean ± SEM (n=3).  
Statistical significance was assured by Student’s t-test. Significance levels are indicated.  
4.4.2. Influence of Notch signaling inhibition on epithelial proliferation 
and survival 
              Based on the previous observations, it was asked if blockage of the Notch 
pathway could influence the level of proliferation in mouse epithelial cells in vitro. To 
answer this question a knock-down of POFUT1 and/or chemical inhibition of the Notch 
pathway by DAPT were employed. 
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4.4.2.1. Inhibition of Notch signaling in the mouse epithelial cell line             
(MLE 12) 
                The MLE 12 cell line was transfected with siRNA directed against murine 
POFUT1. The knockdown efficiency was analyzed by Western blot (Figure 4.13.). The 
protein level of the activated Notch1 receptor was significantly downregulated (~70%) 
72h after transfection with POFUT1 siRNA oligonucleotides. 
 
 
 
Figure 4.13. Analysis of siRNA-mediated knockdown of POFUT1. 
(A) The MLE 12 cells were transfected with the siRNA specific to the mouse POFUT1 mRNA for 72h 
and the protein levels were analyzed by Western blot. ß-actin, served as a loading control.                               
(B) Densitometric analysis of NICD1 protein level expression, normalized to control. All values are given 
as mean ± SEM (n=3). Statistical significance was assured by Student’s t-test. Significance levels are 
indicated. 
 
MLE 12 cells were also treated with DAPT, an inhibitor of Notch activation. The 
reduction in cleaved Notch1 receptor (which is an activated form) was analyzed by 
Western blot (Figure 4.14.A and B). A significant downregulation (~50%) of NICD1 
protein was observed after 54h. In parallel, the mRNA level of downstream gene Hes1 
was also found to be decreased (Figure 4.14.C.). 
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Figure 4.14. Analysis of chemical NICD1 inhibition in MLE 12 cells. 
(A) MLE 12 cells were stimulated with DAPT for 54h and the protein levels were analyzed by Western 
blot. (B) Densitometric analysis of NICD1 protein level expression. All values are given as mean ± SEM 
(n=3) and are normalized to ß-actin, served as a loading control. (C) Real time PCR analysis of Notch 
downstream genes Hes1, 54h after inhibition with DAPT compared to DMSO (dimethyl sulfoxide) 
control. Given is mean ± SEM (n=3) as a fold-increase in mRNA expression in control (normalized to β-
actin expression) versus values obtained from DAPT treated cells.  
Statistical significance was assured by Student’s t-test. Significance levels are indicated. 
 
Following this approach, decreased cell proliferation by [3H]-thymidine incorporation in 
MLE 12 cells was observed upon both, transfection with the siRNA specific for murine 
POFUT1 as well as stimulation with the Notch inhibitor DAPT (Figure 4.15.A and B). 
Additionally, after POFUT1 siRNA knockdown in MLE 12 cells, immunofluorescence 
staining showed lack of a Ki67, a proliferation marker, in parallel to a lack of NICD1 
expression (Figure 4.15.C.).  
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Figure 4.15. Proliferation of MLE 12 cells upon inhibition of Notch signaling.  
(A) [3H]-Thymidine incorporation in MLE 12 cells 72h after POFUT1 knockdown by siRNA.                         
(B) [3H]-Thymidine incorporation in MLE 12 cells following 54h chemical Notch inhibition by DAPT 
(5µM). All values are given as mean ± SEM (n ≥ 10) and are normalized to mock as a control (100%).                               
(C) Colocalization of NICD1 and Ki67 in POFUT1 siRNA knockdown MLE 12 cells, showed by 
immunofluorescence 
Statistical significance was assured by Student’s t-test. Significance levels are indicated. 
 
               This observation raised the question if Notch cleavage inhibition in primary 
mouse AECII would similarly affect proliferation. 
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4.4.2.2. Influence of Notch signaling on proliferation of primary mouse 
AECII 
                To confirm the data obtained with the MLE 12 cell line, primary AECII were 
used to investigate the influence of the Notch pathway on proliferation. Freshly isolated 
primary AECII from saline and bleomycin-treated mice (day 14 post bleomycin 
application) showed a high purity (>90%), as assessed by immunofluorescence for 
epithelial (Pro SP-C, E-cadherin) and mesenchymal (fibronectin and α-smooth muscle 
actin) markers (Figure 4.16.). 
 
 
 
 
Figure 4.16. Purity of primary AECII. 
Pro SP-C, E-Cadherin, fibronectin and α-SMA were all stained by immunofluorescence on 
cytospinspreparation from freshly isolated primary AECII from saline and bleomycin-treated mice (day 
14). Cell nuclei were visualized with DAPI (blue). Original magnification is 40x. 
 
Because of the resistance of primary AECII to transfection, the chemical inhibitor 
DAPT was used to reduce the level of activated Notch1. Proliferation was measured by 
[3H]-thymidine incorporation analysis. Without any stimulation, but on reduced FCS 
(1%) level, an increased proliferation of AECII from bleomycin (day 14) treated 
animals was evident: AECII from bleomycin-treated mice showed more DNA synthesis 
than those isolated from saline treated mice (Figure 4.17.A). Inhibition of Notch by 
DAPT resulted in decreased DNA synthesis only in cells isolated from bleomycin-
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challenged animals as compared to cells isolated from saline treated mice                     
(Figure 4.17.B. and C). 
 
 
 
Figure 4.17. Proliferation of AECII cells isolated from saline and bleomycin (day 14) treated mice. 
[3H]-Thymidine incorporation in AECII isolated from saline (A, B) and bleomycin (A, C) treated mice. 
Cells were plated on plastic and were grown in serum-reduced medium for 40h in absence of any 
stimulation or upon incubation with DAPT (10µM) for 24h or DMSO (0,5%) as a control (B and C). All 
values are given as mean ± SEM (n ≥ 10) and are normalized to cells isolated from saline treated mice 
(100%), cells isolated from saline treated mice incubated with DMSO (100%) or cells isolated from 
bleomycin-treated mice treated with DMSO (100%), respectively.  
Statistical significance was assured by Student’s t-test. Significance levels are indicated. 
 
4.4.3. Expression of NICD1 and the proliferation marker in lung tissue of 
IPF patients  
            To evaluate whether NICD1 may also have any influence on proliferation in 
human samples, imunohistochemistry was performed on IPF sections. As depicted in 
Figure 4.18., colocalization of the intracellular domain of the Notch1 receptor and the 
proliferation marker Ki67 was evident in AECII. 
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Figure 4.18. Expression and colocalization of NICD1 and Ki67 in AECII in lung tissue of IPF 
patients. 
Immunohistochemical staining for NICD1, Ki67 and Pro SP-C, as a marker of AECII in paraffin-
embedded, lung serial sections obtained from IPF patients. The pictures are representative of at least five 
independent experiments. Bar size is indicated. 
 
4.5. Influence of Notch signaling on apoptosis in vitro 
4.5.1. Impact of NICD1 overexpression on apoptosis of MLE 12 cells  
             To evaluate the possibility that Notch1 may have an influence on the 
susceptibility to apoptosis, MLE 12 cells were transfected with the NICD1 encoding 
plasmid and additionally stimulated with the apoptosis inducer-staurosporine.                  
LDH assay and Western blot for cleaved caspase 3 were performed to quantify the 
apoptosis response. As shown in Figure 4.19., overexpression of NICD1 per se did not 
result in apoptosis or necrosis. Moreover, overexpression of the intracellular domain of 
the Notch1 receptor also did not influence staurosporine-induced apoptosis. 
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Figure 4.19. Extent of apoptosis of MLE 12 cells in response to NICD1 overexpression and 
staurosporine treatment. 
MLE 12 cells were transfected with an empty vector or a vector encoding the intracellular domain of the 
mouse Notch1 receptor, incubated for 24h and then treated with staurosporine or DMSO vehicle control. 
Cleaved caspase 3 was analyzed by Western blot (A). Cell death was quantified by LDH assay (B). All 
values are given as mean ± SEM (n=3). Statistical significance was assured by Student’s t-test. 
Significance levels are indicated.  
 
4.5.2. Impact of impaired Notch signaling on apoptosis of MLE 12 cells 
             The data presented in 4.5.1. suggested that Notch1 does not have any influence 
on cell death. To further confirm those results, LDH assays were performed upon 
treatment of MLE 12 cells with POFUT1 siRNA or with the Notch inhibitor DAPT 
(Figure 4.20.A and B). As expected, cell death processes remained unchanged after 
Notch inhibition alone. Moreover, treatment with POFUT1 siRNA or DAPT inhibitor 
did not show any significant impact on staurosporine induced cell death.  
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Figure 4.20. Influence of Notch inhibition on cell death of MLE 12 cells. 
MLE 12 cells were transfected with POFUT1 siRNA for 72h (A) or stimulated with the Notch inhibitor 
DAPT for 54h (B), then left untreated or treated with staurosporine. Extent of cell death was analyzed by 
LDH assay. All values are given as mean ± SEM (n=3). Statistical significance was assured by Student’s 
t-test. Significance levels are indicated.  
 
4.6. Downstream signaling of Notch1 in alveolar epithelial 
cells 
           To identify pathways, which may be involved in the Notch - dependent increase 
in proliferation of mouse alveolar epithelial cells, a genome-wide mRNA microarray 
analysis of MLE 12 cells overexpressing NICD1 vs. a control vector was performed. 
Genes exhibiting a greater than two-fold change in expression were considered as being 
differentially expressed, as described in the Materials and Methods section.                             
For the three predefined timepoints 12h, 24h and 48h post transfection total number of 
genes, which were differentially expressed, was 14, 102 or 237, respectively.                         
To analyze specific pathways involved in Notch1-induced proliferation,                               
the Gene Set Enrichment Analysis was used. 12h after NICD1 overexpression, no 
particular pathway turned out to be differentially regulated. In contrary, prolonged 
overexpression of Notch1 for 24h and 48h resulted in a significantly different  
regulation of several pathways, which are summarized in Table 5. 
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24 h 24h & 48h 48h 
 
Antigen processing and 
presentation 
Atrazine degradation 
Cell adhesion molecules 
(CAMs) 
Cytokine-cytokine receptor 
interaction 
Huntington's disease 
Jak-STAT signaling pathway 
Long-term depression 
Melanogenesis 
Natural killer cell mediated 
cytotoxicity 
T cell receptor signaling 
pathway 
 
Acute myeloid leukemia 
Adherens junction 
Apoptosis 
Axon guidance 
Bladder cancer 
Cell cycle 
Chronic myeloid leukemia 
Colorectal cancer 
ECM-receptor interaction 
Endometrial cancer 
ErbB signaling pathway 
Focal adhesion 
Gap junction 
Glioma 
GnRH signaling pathway 
Insulin signaling pathway 
MAPK signaling pathway 
Melanoma 
mTOR signaling pathway 
Pancreatic cancer 
Prostate cancer 
Regulation of actin cytoskeleton 
Small cell lung cancer 
TGF-beta signaling pathway 
Toll-like receptor signaling 
pathway 
Type II diabetes mellitus 
Ubiquitin mediated proteolysis 
 
Adipocytokine signaling pathway 
Alzheimer's disease 
Aminoacyl-tRNA biosynthesis 
Aminosugars metabolism 
B cell receptor signaling pathway 
Base excision repair 
Biosynthesis of steroids 
Dentatorubropallidoluysian 
atrophy (DRPLA) 
DNA replication 
Fatty acid elongation in 
mitochondria 
Fructose and mannose 
metabolism 
Glycan structures - biosynthesis 
Glycan structures - degradation 
Glycine, serine and threonine 
metabolism 
Glycosylphosphatidylinositol(GPI)-
anchor biosynthesis 
Homologous recombination 
Inositol phosphate metabolism 
Long-term potentiation 
Lysine degradation 
Mismatch repair 
N-Glycan biosynthesis 
Nicotinate and nicotinamide 
metabolism 
Non-homologous end-joining 
Non-small cell lung cancer 
Nucleotide excision repair 
Oxidative phosphorylation 
p53 signaling pathway 
Parkinson's disease 
Pentose phosphate pathway 
Phosphatidylinositol signaling 
system 
Proteasome 
Purine metabolism 
Pyrimidine metabolism 
Regulation of autophagy 
Renal cell carcinoma 
Ribosome 
SNARE interactions in vesicular 
transport 
Thyroid cancer 
Tight junction 
Valine, leucine and isoleucine 
degradation 
VEGF signaling pathway 
Wnt signaling pathway 
Table 5. Pathway analysis performed with Gene Set Enrichment Analysis. 
MLE 12 cells were transfected with NICD1 overexpressing vector for 24h and 48h. Obtained results 
were compare to cells transfected with an empty control vector.  
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One of the pathways that was significantly differently regulated was the mitosis-
activated protein kinase (MAPK) pathway. Both the Notch and the MAPK pathways 
play important roles in many biological processes. Frequently, these two signaling 
pathways intersect to influence common processes, but depending on cellular context 
they cooperate or antagonize each other (108-110). 
            In our microarray experiments data suggested the MAPK pathway differentially 
regulated 24h as well as 48h after NICD1 overexpression (Table 5.). To confirm these 
results, Erk1/2 and Erk5 phosphorylation were analyzed. 48h after NICD1 
overexpression, an increase in Erk5 phosphorylation was observed (Figure 4.21.B) in 
absence of an impact of NICD1 overexpression on phosphorylation of Erk1/2 (p44/42; 
Figure 4.21.A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21. Regulation of MAPK pathway elements after NICD1 overexpression in MLE 12. 
(A) Empty vector or NICD1 overexpression was performed in MLE 12 cells for 48h, followed by 
analysis of Erk1/2 (phospho p44/42 in A) and Erk5 (pErk5 in B) phosphorylation. ß-actin served as                  
a loading control. All the figures are representative of at least two independent experiments. 
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5. Discussion 
5.1. Reactivation of developmental pathways in lung fibrosis 
          IPF is a chronic lung disease of unknown etiology (1). It affects approximately              
500 000 people in the USA and Europe (111). The quality of life progressively 
decreases and patients usually die within 3-5 years after diagnosis. The previous 
difficulties in an effective therapy indicate our incomplete understanding of the 
pathogenesis of idiopathic pulmonary fibrosis. The only available treatment is lung 
transplantation and a new drug – pirfenidone, which may represent a potentially 
important advance in IPF therapy (11-14, 17). 
          One of the histopathological features of IPF is the alteration of the alveolar 
epithelium. It has been proven that hyperplastic type 2 pneumocytes play a role in the 
cycle of continued epithelial cell injury and the ineffective re-epithelialization in 
association with myofibroblast activation. Although significant advances have been 
made in understanding reasons for this abnormal process, the specific cellular and 
molecular mechanisms that contribute to incorrect epithelial repair and the resulting 
disease progression, remain unclear (23, 24). Hope for IPF patients may arise from 
novel and more accurately targeted strategies. Reactivation of signaling pathways, 
essential for lung development, is suspected to play a major role in the pathogenesis of 
IPF and may be a useful target for disease treatment. Lung development is dependent 
upon precise temporal and spatial control of cell proliferation, migration and 
differentiation processes that are mediated by diverse interactions between various cell 
types. Numerous signaling and transcriptional pathways, including e.g. sonic hedgehog 
(Shh), Wnt, bone morphogenetic protein 4 (Bmp4), vascular endothelial growth factors 
(Vegfs), transforming growth factor (TGFβ), fibroblast growth factors (Fgfs), and  
Notch have already been implicated not only in lung morphogenesis (105, 112-117). 
Their role is constantly investigated in animal models, as well as human diseases and 
reactivation of developmental programs has been shown in COPD or PAH (9-10). The 
possibility, that some of these pathways are key players in the re-programming of 
alveolar epithelial cells to restore adult lung structure and function after injury, validates 
them to be important factors in the pathogenesis and treatment of pulmonary fibrosis. 
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           In our study, we were particularly interested in developmental pathways which 
may play a role in alveolar epithelial repair in IPF patients. We performed microarray 
experiments on microdisected septae and whole lung homogenates isolated from IPF 
lungs, compared to samples from healthy organ donors. As we focused our research on 
pathogenesis of IPF, we concentrated our effort on pathways characterized by 
microarray experiments performed on septae from “normal” appearing areas (which was 
assumed to represent an early stage of disease). Our results suggested that TGFβ and 
Wnt networks and the Notch signaling pathway, which were mentioned above, were 
differentially regulated in those samples. 
           TGFβ pathway elements are known to be expressed at high levels during normal 
mouse lung development. The lungs of the mice with targeted disruption of the TGFβ2 
gene did not show any abnormalities with regard to lung structure, but the animals died 
around birth because of respiratory failure. On the contrary, TGFβ3 null mutant mice 
had a specific neonatal lethal lung phenotype characterized by developmental delay, 
with alveolar hypoplasia, reduced expression of surfactant protein C and missing 
alveolar septal formation (118). It is well known that TGFβ is secreted by epithelial 
cells, macrophages, endothelial cells, and fibroblasts (108). The impact of the TGFβ 
pathway on IPF is undeniable (11, 119). As mentioned previously, a novel drug 
(pirfenidone), which has shown some efficacy in clinical trials and which is now 
authorized in the EU, has been shown to regulate the activity of this cytokine (120, 121). 
TGFβ can drive EMT, a process where epithelial cells undergo transition to                            
a mesenchymal phenotype, giving a rise to fibroblasts and myofibroblasts. The 
occurrence of TGFβ1-induced EMT has been clearly demonstrated in AECs from both 
human and rat origin (122, 123). TGFβ is also known to induce intracellular matrix 
(ECM) production, to inhibit alveolar epithelial proliferation and to promote epithelial 
apoptosis (124, 125). Sime et al. show that TGF-β1 overexpression in vivo, using 
adenoviral gene transfer, induces progressive pulmonary fibrosis in rats. In addition, the 
inflammatory response has not been observed in the lungs, but presence of fibroblastic 
foci was confirmed (126). 
          Another pathway which plays a major role in lung development and adult tissue 
homeostasis is the Wnt/β-catenin network (127). Epithelial cell–specific expression of 
constitutively active β-catenin leads to epithelial cell dysplasia and ectopic 
differentiation of alveolar epithelial type II cells in the conducting airways during 
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embryonic development. Enhanced activity of β-catenin also caused pulmonary tumors 
and air space enlargement in a subset of adult mice (128). In contrast, lung epithelial 
cell–specific deletion of β-catenin results in blocked alveolar epithelial cell 
differentiation, resulting in a lung structure composed primarily of conducting airways, 
thus demonstrating a critical requirement of β-catenin for regular formation of alveoli 
(129). In IPF, the Wnt/β-catenin developmental network is one of the core signal 
transduction pathways involved in abnormal wound repair and fibrogenesis. WNT-1-
inducible signaling protein (WISP-1) is upregulated in humans with IPF and was shown 
to mediate pulmonary fibrosis in mice (130). Moreover, pharmacological inhibition of 
Wnt/beta-catenin/CREB binding protein signaling is capable of reversing 
experimentally induced pulmonary fibrosis. It has been shown that in response to 
upregulation of Wnt target genes, increased proliferation of alveolar epithelial cells 
occurs (130, 131). Activation of Wnt/β-catenin signaling is also known to promote 
alveolar epithelial survival, migration, and differentiation towards an AT1-like 
phenotype (132). This pathway is also known to take part in the EMT process 
employing TGFβ/SMAD3 signaling (133, 134).  
           Our results obtained from the microarray analysis indicated an involvement of 
the Notch signaling pathway in IPF with a potential impact on the alveolar epithelium. 
The Notch pathway is well known to either promote or to repress proliferation, cell 
death, maintain stem cell phenotype and differentiation during embryonic and adult 
development. Notch is perfectly suited to precisely regulate cell-cell communication in 
the lung (5-7, 135). Because of these features the Notch pathway may turn out to be 
centrally involved in the pathogenesis of IPF and may have a great impact on alveolar 
epithelial re-epithelialization. Concerning pulmonary fibrosis the Notch signaling 
pathway has been found to be implicated in the EMT process via TGFβ/SMAD3 
signaling (93, 136-137). Interestingly up to now, there is neither data on the Notch 
signaling pathway element expression in IPF nor on the influence of Notch activation 
on alveolar epithelial proliferation, differentiation or survival. 
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5.2. Reactivation of the Notch signaling pathway in lung 
fibrosis and other diseases 
           The rationale for examining the Notch pathway in lung fibrosis does not 
exclusively stem from the knowledge of the influence of Notch on the regenerative 
response to injury in adult tissue (129-141) but also from a growing number of studies 
showing that Notch signaling may play a significant role in the process of fibrosis in 
organs such as kidney, skin and heart (95, 98, 142). In addition, reactivation of                   
the Notch developmental pathway was demonstrated in many other chronic lung 
diseases like chronic obstructive pulmonary disease (COPD) and pulmonary arterial 
hypertension (PAH) (9, 10). The evidence of the Notch axis involvement in various 
pathologies directs us to further investigate the possible role of the Notch pathway in 
pulmonary fibrosis. 
           Prior to the determination of the potential function the expression of Notch 
signaling pathway elements was examined. The NOTCH1 receptor and DLL1 ligand 
gene expression were only slightly upregulated in IPF lungs. Western blot analysis of 
IPF samples revealed upregulation of the NOTCH1 receptor and DLL1 ligand but of no 
other Notch receptor or ligand. Also upregulation of the Notch downstream target HES1 
was confirmed in IPF and proved activated Notch signaling. Elevated expression of 
NOTCH1 and DLL1 was also observed in the animal model of bleomycin-induced lung 
fibrosis. NICD1 receptor was found to be upregulated from day 7 to day 21 and DLL1 
ligand expression was significantly increased at day 21 and 28 post bleomycin 
application.  
           Such activation of the Notch signaling pathway has also been observed in               
the skin and lungs of mice with HOCl-induced systemic sclerosis, as well as in the skin 
of SSc patients (143). Comparable results to ours were also obtained in the previously 
published study of tubulointerstitial fibrosis (TIF), where increased expression 
especially of NOTCH1 and JAGGED1 was observed in patients with TIF and in the 
folic acid–induced TIF model. Accordingly, upregulation of HES1 was noticed (98). 
Moreover, results reflecting our data were described by Ma et al. who revealed that 
NICD3 and Hey1 are upregulated after 5-fluorouracil induced injury of the rat tracheal 
epithelium (144). It is also known that Notch1 plays a major role in the control of the 
adaptive response of the heart to stress conditions (139) and is activated during liver 
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regeneration (141), further confirming a possible involvement of the Notch pathway in 
pathomechasim of lung fibrosis.  
            In principle, the activation of Notch1 could be achieved by increased interaction 
with Notch ligands, which leads to proteolytic cleavage of the receptor by the                       
γ-secretase complex. Moreover, several mechanisms were reported to regulate 
activation of Notch1, including the γ-secretase complex stability and activation (145), 
endocystosis and trafficking of the Notch1 receptor/Notch ligands or various 
posttranslational modifications, namely phosphorylation, ubiquitylation, hydroxylation 
and acetylation (83). We can hypothesize that in IPF NOTCH1 and DLL1 proteins 
interact with each other to activate cleavage of the Notch1 receptor, which then plays               
a role as a transcription factor and increases expression of target genes such as HES1. 
Increased Notch pathway activation may indicate a role of this network in pathogenesis 
and/or progression of IPF as well as it was observed in other fibrotic diseases.  
5.3 Alveolar epithelium as a target cell type for Notch 
signaling  
            As mentioned before, a sequential alveolar epithelial injury occurs in IPF, with 
epithelial cell damage and an impaired wound-healing (1). It is for this reason that 
AECII cells are at the center of interest when studying IPF pathology. AECII have the 
potential to regenerate AECI cells and to repair the injured alveolar epithelium (27). 
They are also known to interact with fibroblasts and extracellular matrix (146-148).  
            In our study, we confirmed NICD1 expression predominantly in hyperplastic 
AECII of IPF lungs. Increased staining in cleaved NOTCH1 was previously also 
observed in tubular epithelial cells of human TIF (98). We observed characteristic 
patterns where one cell expressed NOTCH1 in cytoplasm, while the neighbour AECII 
cell showed localization of NICD1 in the nucleus. During the injury a similar situation 
was observed in NICD3 localization of rat tracheal epithelial cells. It was suggested that 
Notch activation plays a role in the maintenance of an undifferentiated state of epithelial 
cells and the promotion of proliferation of cells (144). We suggest that NICD1 may 
have an impact on AECII transdifferentiation in AECI. It is in line with such theory that 
AECII may represent a pool of progenitor cells (27, 28) and Notch may play                         
a significant role in epithelial repair after injury (to be discussed further). Additionally 
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our immunohistochemistry and Western blot analysis revealed a basal level of NICD1 
expression in donor lung samples, indicating that activation of the Notch signaling 
pathway is required for lung homeostasis (Figure 5.1). Since we also observed 
upregulation of the DLL1 protein in IPF samples, we performed localization studies of 
this ligand. We confirmed that, similar to NOTCH1 expression, DLL1 localized 
predominantly in hyperplastic type II cells. We therefore assume that there can be two 
possibilities of ligand and receptor expression in the same cell. One possibility is that 
the Notch ligand is presented by neighbouring cells (trans interactions) and inhibitory 
interaction with ligand co-expressed in the same cell (cis interactions) can occur, as 
suggested by Cordle et al. (71). This could explain why we see activated NOTCH1 only 
in a part of the alveolar epithelial cells. Another explanation could be that the NOTCH 
receptor can be activated by the ligand in the very same cell (e.g. on the membrane of 
endocytosis compartments; 44, 149). Following this line of reasoning, we were also able 
to identify DLL1 expression in the nucleus. It was recently discovered that DLL1 can be 
constitutively cleaved by ADAM10 and γ-secretase like a complex and that the 
intracellular region of DLL1 can be partly localized in the nucleus. The DLL1-
intracellular domain was shown to bind to NICD1 in the nucleus hence disrupting the 
Notch1-RPBJk-MAM activation complex (150). We also localized expression of HES1 
protein in hyperplastic AECII, although this was not an exclusive finding. HES1 
expression, which, as we mentioned before, is known to be a target gene of the Notch 
signaling pathway, indicates the activation of this network in epithelial cells of IPF 
lungs. A literature search revealed that localization of HES1 in the cytoplasm has 
recently also been confirmed in mucus cells of bronchioles in IPF patients (151). 
According to more recent data, expression of Hes1 can also be regulated by Sonic 
Hedgehog pathway (152) and histone deacetylases (HDACs) (153). The complex 
regulation of the HES1 gene may be the reason for the versatile expression of HES1 in 
IPF lungs.  
            Furthermore, we studied the localization of the Notch1 receptor in                     
the bleomycin-induced animal model of pulmonary fibrosis. In line with the results 
obtained with human IPF samples, we confirmed expression of NICD1 in alveolar 
epithelial cells 14 days post bleomycin instillation. The Notch1 receptor can also be 
seen in other cell types, which we assume to be inflammatory cells. It is worth to 
remind that at day 7 after bleomycin instillation, the NICD1 protein expression was 
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already significantly increased in lung homogenates. As Notch1 is known to be 
expressed in T cells of asthmatic mice, we can not exclude the possibility that                 
the Notch pathway is also involved in the inflammatory responses observed in               
the bleomycin mouse model (154).  
            Analogical results to ours were obtained in renal tubular epithelial cells, which 
play a prominent role in tubulointerstitial fibrosis (98). Immunohistochemistry of 
cleaved Notch1 showed expression of this protein in sections obtain from kidneys of 
folic acid injected mice (98). In addition, Notch activation was observed to be critical 
for proper reconstruction of the intestinal epithelium in mice with dextran sodium 
sulfate (DSS)-induced colitis. Furthermore, NICD1 overexpression was demonstrated to 
promote corneal epithelial wound healing (155, 156). 
Collectively, these data encourage us to speculate that an improper level of 
Notch activation in the lung epithelium can be implicated in failed                                  
re-epithelialization after alveolar injury. We can suggest that marked and uncontrolled 
activation of the Notch1 receptor in AECII may be a factor which plays an important 
role in the altered process of alveolar epithelium repair, damaged in pulmonary fibrosis. 
5.4. Impact of Notch signaling on proliferation and possible 
differentiation  
          Until now, different types of cells were characterized as a stem cell/progenitor 
cell of the distal lung. Firstly, Kim et al. identified bronchoalveolar stem cells (BASCs), 
which where found in the bronchoalveolar duct junction in the adult mouse. They 
demonstrated that BASCs may proliferate during epithelial repair in vivo and are 
capable of multipotent differentiation and self renewal in culture. After bleomycin 
treatment a significant increase of BASCs were observed 14 days after installation, 
when AECI depletion becomes evident. In vitro, culture of BASCs on Matrigel shows 
multilineage differentiation (CCA, SP-C and aquaporin-5 markers were identified) 
(157-159). Secondly, Chapman et al. identified an α4β6-expressing epithelial cell 
located both in bronchoalveolar junction regions and alveoli. This cell type obviously 
greatly contributed to epithelial regulation after exposure to bleomycin. In cell culture 
or in organoid experiments, β6+ cells also differentiated into either airway or alveolar 
epithelial cells (160). Thirdly, an increase of alveolar epithelial type II cell (AECII) 
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population has been observed in the distal alveolar epithelium after various insults 
including smoking, silica installation or pneumonectomy (161, 162). It is possible that, 
in pulmonary fibrosis, BASCs and α4β6-expressing cells may play a role as a 
stem/progenitor cell for AECII. A microenvironment, in which stem cells reside, 
provides essential signals required for stem cell identity and for regulation of 
asymmetric cell division, resulting in one daughter cell retaining the stem cell 
phenotype and other cells undergoing differentiation (163). We may speculate that after 
injury of the alveolar epithelium, stem cells divide and a part of those daughter cells 
differentiate into AECII, which themselves can then serve as a progenitor to rebuild the 
AECI layer. Dynamic and magnitude of the injury can possibly influence that 
progenitor cell’s response. Chapman et al. demonstrated that, at day 14 post bleomycin, 
SP-C-positive AECII largely derived from non SP-C expressing progenitor cells at the 
time of injury, adding evidence to the hypothesis of α4β6-expressing cells serving as a 
progenitor cell for AECII (160). We must emphasize that in case of IPF, after injury to                       
the alveolar epithelium, the remaining AECII may begin to proliferate in order to assist 
BASCs in their attempt to restore critical AECII numbers. Unfortunately, this effort of 
re-epithelialization fails since hyperproliferaton of AECII is not accompanied by 
concomitant transdifferentiation of AECII into AECI cells (164). Accordingly, it has 
been shown that proliferation and absence of transdifferentiation of AECII is   a critical 
step in the development of lung fibrosis (164, 165). It was demonstrated that balanced 
proliferation of AECII can play a very important role during the proper                                 
re-epithelialization process in lung fibrosis (1, 23-24); and continuous proliferation of 
type II cells was observed in a hyperplastic epithelium of the fibrotic lung (162). In the 
bleomycin-induced mouse model the increase of [3H]-thymidine incorporation was 
shown in AECII, after epithelial injury (28). We also confirmed that cells isolated from 
mice at 14 days post bleomycin-challenge showed a significant increase in DNA 
synthesis compared to cells isolated from control saline mice. Analogical results were 
described in the literature where AECII were isolated from mice 14 days post 
bleomycin installation compared to cells isolated from mice 5 days post bleomycin 
installation (130). Additionally, a study by Fukumoto et al. revealed increased PCNA 
protein abundance in AECII isolated from mice challenged with bleomycin, suggesting 
increased proliferation of these cells (166).  
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            In our study, we focused mainly on mechanisms resulting in                                    
a hyperproliferative state of AECII in lung fibrosis. In principle, it had been suggested 
that progenitor AECII cells may remain quiescent, undergo symmetric rather than 
asymmetric division and undergo apoptosis or transdifferentiate to AECI in response to 
lung injury (5, 167-169). The process of symmetric cell division is known to be very 
common during wound healing and regeneration (170). Taking into consideration our 
previous results (upregulation of the Notch1 receptor in “hyperplastic” AECII), we 
believe that the Notch signaling pathway could have a major impact on these processes 
in a fibrotic lung. Notch is known to be an important molecule in specifying cell fate 
(171). It plays a central role in asymmetrical division of stem cells (172), and cells that 
have a higher level of Notch activation continue to divide while those with lower levels 
begin to differentiate (173). Studies in the field of lung development revealed that 
constitutive NICD1 expression in the distal lung epithelium prevents the differentiation 
of alveolar epithelial cells (105). In these mice, the normal alveolar structure was lost. 
Instead enlarged cysts formed by cells lacking alveolar epithelial markers, but 
expressing molecules characteristic for proximal airway epithelium, were observed. On 
the other hand, other studies revealed that inhibition of the Notch pathway in a lung 
epithelium does not influence the distal airway differentiation (101, 102). These data 
highlight the importance of precise Notch signaling regulation in the lung development 
and the putative destructive effect of malevolent NOTCH1 activation. 
To confirm our assumption that Notch plays a role in epithelial proliferation we 
performed a series of experiments in vitro. We were able to clearly colocalize NICD1 
and Ki67 in hyperplastic AECII in fibrotic regions of IPF lungs confirming that these 
cells are actively proliferating. Increased DNA synthesis and upregulation of PCNA 
expression was noticed in MLE 12 cells following transfection of NICD1. Conversely, 
inhibition of the Notch signaling pathway significantly decreased [3H]-thymidine 
incorporation, which clearly indicates lower a DNA synthesis level. Furthermore, after 
knock down of the Notch processing enzyme, POFUT1 in MLE 12 cells we could not 
observe any colocalization of the Notch1 receptor and   the Ki67 proliferation marker. 
We can speculate that when Notch activation is insufficient it can lead to a lack of 
epithelial cell proliferation and afterwards improper repair after injury, which can be 
observed e.g. in diffuse alveolar damage (Figure 5.1.). Moreover, Xing et al. confirmed 
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in an experimental model of naphthalene airway injury that activity of Notch1 is 
required for normal repair of the proximal airway epithelium (189). 
To validate results obtained with MLE 12 cells we investigated primary AECII 
cells isolated from bleomycin-treated mice. Treatment with the γ-secretase inhibitor, 
DAPT, resulted in a significant reduction of DNA synthesis in mouse primary AECII 
cells, confirming the data obtained with MLE 12 cells. Taken together, our data indicate 
that Notch signaling may well play a central role in injury-driven hyperproliferation of 
AECII in fibrotic lung disease. In relation to those observations made in the lung, Notch 
was previously identified as an activator of cell proliferation in kidney fibrosis (98). 
Recently, it was demonstrated that overexpression of NICD1 in the mouse distal lung 
epithelium leads to hyperplasia and proliferation of cells in the alveolar space (174). 
Additionally, the Notch signaling pathway is also known to have influence on 
proliferation processes in other epithelial cells such as the human corneal epithelium 
(175) and retinal pigment epithelium (93).                  
As mentioned above AECII are also proven to transdifferentiate into AECI           
in vitro. Konishi et al. documented decreased expression of the AECI marker in IPF 
lungs. This implicates potential loss of type I alveolar epithelial cells and lack or 
improper differentiation of ACEII into AECI in this disease (164). It is known that 
active Notch signaling can increase epithelial cell proliferation and decreases 
differentiation in human corneal epithelial cells (175). Moreover, as mentioned before, 
it has been suggested that Notch may play a role in keeping epithelial cells in an 
undifferentiated state and promoting proliferation of rat trachea epithelial cells (144). It 
seems that the balance between proliferation and differentiation of AECII can be crucial 
for proper re-epithelialization in the alveolus and may contribute to the pathogenesis of 
pulmonary fibrosis. 
5.5. Downstream signaling of Notch responsible for enhanced 
proliferation 
              Since the Notch pathway appears to be an important player regulating alveolar 
epithelial homeostasis, we were interested in the identification of pathways playing              
a role in the Notch-dependent increase in epithelial proliferation. The results of our 
mRNA microarray experiments on MLE 12 cells suggested that one of                           
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the signaling pathways which are differentially regulated after NICD1 overerexpression 
is the mitogen-activated protein kinase (MAPK) pathway. It is known that activated 
MAPKs participate in the control of epithelial cell proliferation and apoptosis and are 
activated by various stimuli (178, 179). Moreover mRNA expression of MAPK 
signaling cascade was also altered in microdisected septae from “fibrotic” areas of IPF 
lungs. Yoshida et al., showed differentially regulated expression of activated MAPKs in 
lung homogenates from patients with IPF (180). It has previously been demonstrated 
that a reduction activated Erk1/2 in alveolar epithelial cells was accompanied by                     
a progression of fibrosis (180). It was suggested that dampened activation of Erk1/2 
may be associated with progression of epithelial cell damage, whereas phosphorylated, 
activated Erk1/2 may play a protective role in AECII apoptosis (180). Our investigation 
did not reveal altered phosphorylation of Erk1/2 in MLE 12 cells in response to NICD1 
overexpression suggesting that Erk1/2 is not a target of activated the Notch signaling 
pathway. Additionally, we investigated phosphorylation of Erk5 which is implicated e.g. 
in cellular survival and proliferation (181). We found that NICD1 overexpression in 
MLE 12 cells induced phosphorylation of Erk5. Reddy and colleagues reported 
expression of Erk5 in epithelial cell lines derived from proximal (HBE-1) and distal 
(Clara–like H441), as well as in the alveolar epithelial type II like cell line, A549 (182). 
To this day, expression and post-translation modification of Erk5 has neither been 
analyzed in human IPF nor in the bleomycin model of pulmonary fibrosis. Despite this, 
Erk5 was suggested to play a role in the pathogenesis and progression of lung fibrosis 
induced by asbestos (176). Scapoli et al. showed that Src-dependent Erk5 
phoshorylation is required for mouse lung epithelial cell (C10) proliferation induced by 
asbestos (176). Our data and results reported by other groups allow us to speculate that 
Erk5 may be the downstream effector of Notch1 mediated epithelial proliferation. 
5.6. Impact of Notch activation on alveolar epithelium cell 
death 
           Studies undertaken by Allen et al. revealed that in mice overexpressing NICD1 
in the distal epithelium, the AECII undergo intensive proliferation which is followed by 
increased apoptosis (174). It is already known that uncontrolled proliferation can be 
associated with a high level of apoptosis (100). Proliferation and apoptosis of 
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epithelium cells was also reported in IPF patients by Qunn et al. (4) and Korfei et al. (2). 
DNA damage and apoptosis in lung epithelial cells have also been reported in acute 
lung injury (184) and diffuse alveolar damage (185), as well as in IPF (3, 186). 
Moreover, the telomerase activity seems to be diminished in IPF, resulting in premature 
telomere shortening. According to previously published studies, telomerase expression 
is generally restricted to cells with the capacity to undergo proliferation and may also be 
an attribute of AECII (187, 188). Encouraged by this evidence, we investigated whether 
Notch signaling is involved in the pro-apoptotic process and could be responsible for 
the cell death of lung epithelial cells in vitro. However, we demonstrated that activation 
of NICD1 did not influence apoptosis by altering the level of cleaved caspase 3 or LDH 
release with and without cell death inducer. We also were not able to observe changes 
in cell death after the Notch pathway was inhibited. We understand that this observation 
can be explained by our experimental settings, mainly because we performed transient 
NICD1 overexpression and transient Notch inhibition. The duration of our in vitro 
experiments may not have been sufficiently long to reflect in vivo studies performed by 
Allen et al., where overexpression of NICD1 in AECII induced intensive proliferation 
followed by apoptosis of alveolar epithelial cells (174). We also have to remember that 
our survival studies have been performed employing an immortalized cell line, which 
may not sufficiently mimic the alveolar epithelium in vivo. However, similar results to 
ours were reported by investigators studying kidney fibrosis, documenting no influence 
of the Notch signaling pathway on epithelial apoptosis (98). 
5.7. Conclusions and future directions  
    Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive, fibrotic lung 
disease (11). The presently proposed pathogenic mechanism in IPF proposes occurrence 
of a sequential alveolar injury, which leads to the epithelial cell damage. Under normal 
conditions, the repair process ensures proper re-epithelialization and this mechanism 
seems to be impaired in IPF (1). For this reason we focused our effort on alveolar 
epithelial cells, which are assumed to play a main role in distal alveolar repair in 
pulmonary fibrosis. 
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Figure 5.1. Differential regulation of Notch pathway activation may have a diverse impact on 
AECII proliferation and transdifferentiation into AECI. 
     In this investigation, we hypothesized that expression of Notch signaling 
pathway elements and Notch activation can be a factor playing an important role in 
proliferation and regeneration of the alveolar epithelium in IPF. We demonstrated the 
activation of the Notch signaling pathway in lungs of IPF patients and in mice the 
bleomycin model of pulmonary fibrosis. Moreover, our results provide evidence that 
differentially regulated elements of the Notch pathway are restricted mainly to alveolar 
epithelial cells in the injured lung. Furthermore we observed characteristic patterns 
where subpopulations of AECII cells expressed Notch1 in cytoplasm and neighboured 
AECII cells showed localization of Notch1 in the nucleus. In addition, we observed that 
Notch plays a major role in epithelial cell proliferation in vitro. It can be suggested that 
Notch activation plays a role in maintaining an undifferentiated state and promotes 
proliferation among the AECII cell population. We have also found that NICD1 
overexpression in MLE 12 cells induced phosphorylation of Erk5 and this allows us to 
speculate that Erk5 may be a downstream effector of Notch1 activation. Furthermore, 
influence of the Notch signaling pathway on epithelial apoptosis was not observed. 
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    To further investigate the impact of the Notch signaling pathway on                      
the mechanism preventing differentiation of AECII to AECI in vitro and in vivo analysis 
is needed. Moreover, since isolated primary cells do not reflect complex interactions in 
intact lungs, it would be beneficial to investigate proliferation and apoptosis of alveolar 
epithelial cells in mice lacking Notch1 or transgenic animals with Notch1 
overexpression. It would also be also beneficial to use transgenic mice with inhibition 
or/and activation of the Notch signaling pathway in AECII cells to test the Notch effect 
on the fibrosis process after bleomycin installation. This experiment would answer the 
question whether the Notch pathway is a reasonable target for a therapy of IPF. As it is 
known, available treatment strategies are still very limited. Kavian et al. already showed 
that the inhibition of the Notch pathway can prevent the fibrotic process and become             
a useful treatment of systemic sclerosis in the future (143). In addition, since Erk5 is 
implicated in the control of cell proliferation and survival, it is reasonable to test 
whether ablation of Erk5 in NICD1-overexpressing cells impacts the proliferation rate. 
Additionally, future investigation could answer the question whether Notch activation 
correlates with Wnt or TGFβ pathways, which are well known to play a role in 
pulmonary fibrosis.  
     In conclusion, our results revealed that the Notch pathway is highly activated in 
AECII in pulmonary fibrosis and has an influence on epithelial cell proliferation. AECII 
serves as a progenitor cell and after injury, AECII seems to undergo symmetric cell 
division to replenish their reduced population which may not be accompanied by 
transdifferentiation into AECI. Together, our findings suggest that improper activation 
of Notch signaling could be the reason for failed re-epithelialization, during repair of 
the damaged lung in IPF (Figure 5.1).  
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